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Epilepsy is a chronic and often progressive brain disease affecting 
approximately 1 to 2% of the population. Mono anti-epilepsy drug therapy has 
always become ineffective as the disease progress so that combined polytherapy 
is necessary in clinical practice. The hypothesis for this project was that the 
co-administration of two or more anti-epilepsy drugs would lead to 
neuropharmacokinetic interactions in the brain and such interactions may not be 
necessarily accompanied by conventional pharmacokinetic interactions in the 
plasma.  
 
To test the hypothesis, microdialysis and conventional jugular vein cannulation 
technique were used to obtain rat brain extracellular fluid and plasma samples 
following intra-peritoneal (i.p.) administration of antiepileptic drugs (AEDs) 
given alone or in combination at low and high doses. Phenytoin, felbamate and 
carbamazepine were chosen as the model drugs due to their extensive use and 
potential interactions. The HPLC and LC-MS/MS analysis methods for these 
three model drugs were established. The methods were validated to be specific 
and accurate, and were successfully applied to an in vivo pharmacokinetic study. 
Neuropharmacokinetic and conventional pharmacokinetic interactions between 
 VIII 
phenytoin and felbamate as well as between phenytoin and carbamazepine were 
investigated by comparing drug concentrations in brain extracellular fluid and 
plasma. 
 
A combined administration of AEDs at the low dose did not significantly affect 
their bioavailability in the brain as well as in the plasma, whereas that at the 
higher dose enhanced significantly their brain bioavailability even though the 
plasma concentrations of the AEDs still remained the same compared to their 
respective levels when given alone. The overall findings of this study suggest 
that at a certain non-toxic dose, co-administration of the AEDs caused 
neuropharmacokinetic drug interactions, possibly through modulation on brain 
drug transporter activities. Also, the findings provide a direct in vivo evidence 
for neuropharmacokinetic interactions. Precautions are thus warranted with 
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1.1 Epilepsy and antiepileptic drugs 
 
Epilepsy is the second most common neurological disorder next to stroke, 
affecting approximately 1 to 2% of the population in the world (1). An 
epidemiological survey has noted a 0.38 % life-time prevalence of epilepsy in 
Singapore (2). Epilepsy is a chronic and often progressive brain disease that its 
treatment may require antiepileptic drug (AED) for many years. Though 
considerable progress has been made in understanding the pathogenesis of 
seizures and epilepsy, little is known about the pathological and physiological 
basis of many seizure types and syndromes (3; 4). As the consequence, the 
current drug therapy of epilepsy merely aims at the control of symptoms, i.e., 
keeping the patient free of seizures without interfering with normal brain 
function. 
 
AED monotherapy refers to the therapeutic method to epilepsy patients using 
only one AED. The efficacy of AED monotherapy in the treatment of epilepsy 
has been well established so that AED monotherapy is the first choice for 
epileptic patients (5; 6; 7). It has been shown that about 60-70% of newly 
diagnosed patients can have their seizures controlled effectively by only one 
AED, and up to half of the remaining 30-40% of patients can also have their 
 3 
seizures controlled after switch to an alternative AED (8).  
 
The advantages of AED monotherapy include less acute and chronic toxicity 
associated with unnecessary AED polytherapy. However, for those patients who 
have difficult-to-treat epilepsy and do not respond to monotherapy, a 
combination of two or more AEDs may be necessary to allow the freedom of 
seizures (9). Additionally, all new AEDs are usually given at first prescription as 
add-on therapy in patients with chronic refractory partial epilepsy. Therefore 
polytherapy will initially be the only option for new AEDs (10). 
 
1.2 AED drug interactions and neuronpharmacokinetics 
 
1.2.1 AED drug interactions 
 
Drug interactions may occur when two or more drugs are administered 
simultaneously. The therapeutic relevance of drugs interactions is important not 
only when drugs are co-administered, but also when one or more drugs are 
removed from a multiple drug regimen. Interaction processes go into reverse 
when an interacting drug is discontinued from a patient’s drug regimen; 
therefore physicians must be aware that drug discontinuation may have a 
 4 
serious impact on the efficacy or toxicity of the remaining drugs (8). 
 
It has been estimated that a drug interaction is the main cause among 6% of 
patients experiencing AED intoxication (11). Careful consideration must be 
given to the consequences of any drug interaction between the various AEDs 
that are co-administered. The full understanding of drug interactions in AED 
polytherapy will provide evidence to design a rational use of combined AEDs to 
enhance the treatment efficacy as well as to minimize the toxicity. 
 
In the past, the drug interactions related to epilepsy treatment were usually 
based on the empirical observations. It was difficult for physicians to determine 
the potential of AEDs interactions. Current observations on AED drug 
interactions are mainly based on studies involving cytochrome P450 (CYP). For 
example, phenobarbital, phenytoin and carbamazepine are potent enzyme 
inducers which are able to increase the level of capacity of various CYP and 
UGT isoenzymes. Co-administration of one of these inducers may result in an 
increase in the rate of metabolism of an affected drug, followed by a decrease in 
its plasma concentration, and possibly a loss of clinical efficacy, particularly 
when both the co-administered drugs have a common CYP isoenzyme. Also, the 
amount of enzyme induction depends on the dose of the inducing drug. It has 
 5 
been reported that the plasma concentration of valproate was reduced to 49% 
when coadministered with phenytoin (12). To date, the cytochrome P450 
enzyme system responsible for the metabolism of AEDs has been well studied 
and is thought to be potentially the major targets for interference by 
concomitantly administered drugs (13). This hypothesis leads to the 
development of in vitro screening assays for studying the interactions of new 
AEDs with the cytochrome P450 enzyme system. Consequently, in vitro 
screening for drug interaction can be undertaken early in the development of 
AEDs, and the investigation of pharmacokinetic interactions is usually carried 
out in phase I and II clinical studies (14). 
 
Research on AEDs’ interaction not only offers us more knowledge about the 
rational clinical use of AEDs but also becomes gradually an essential step in the 
development of a new AED. Except for metabolic enzyme, other factors may 
also play important roles in AED interaction. Drug transporter system that 
located in the brain is among such factors. However, even though more and 
more attention has been paid to this field (15; 16), there is still insufficiency in 
this challenging area due to the technique limitation or hardship in correlation 





Pharmacokinetics is the study of time course of absorption, distribution, 
metabolism and elimination (ADME) of drugs in the body. In many cases, 
pharmacokinetics refers to the temporal changes of drug concentrations in 
plasma because the pharmacological and toxicological effects of many drugs are 
related to drug concentration in plasma. Here neuropharmacokinetics refers to 
the temporal changes of drug concentrations in brain. In contrast to 
conventional pharmacokinetic studies using plasma samples, 
neuropharmacokinetic research mainly involves the analysis of drug ADME in 
brain. Neuropharmacokinetics study is especially important for those drugs 
whose action sites are located in brain such as AED and anesthetics. 
Neuropharmacokinetics knowledge will let us understand better how an AED 
take effects in brain. There has been also increasing demand of knowledge on 
neuropharmacokinetic interactions that take place in the brain, in addition to the 
peripheral compartment. Not only would this lead to a better understanding of 
some of the drug interactions that are observed in the clinical practice, but also 
would it enable researchers to distinguish between pharmacokinetic and 
pharmacodynamic interactions that take place at the site of the drug activity. A 
greater understanding of the pharmacodynamic interactions, in particular the 
 7 
synergistic effects that enhance the therapeutic index of drug combinations, 
should allow drug combinations to be used for the maximal benefit of the 
patient. But to date, little work has been done on pharmacokinetic interactions 
which take place in brain. Limited accessibility of cerebrospinal (CSF) in 
humans, the availability of only single time-point determinations of CSF, and 
the lack of sensitive microanalytical techniques for drug assay in 
small-specimen samples have invariably prevented the systematic study of such 
interrelationships in humans. 
 
1.3 Role of multidrug transporters in the AEDs neuropharmacokinetics 
and pharmacoresistence 
 
1.3.1 Multidrug transporters in the blood-brain barriers and 
blood-cerebrospinal fluid barriers 
 
The entry of drugs into the brain is restricted by either the blood-brain barrier 
(BBB) or the barrier between blood and brain (17). The BBB had been 
considered to be an anatomical barrier that absolutely restricted the passage of 
certain substances into the brain. However, besides passive diffusion, drugs may 
also enter and leave the brain by carrier-mediated transport processes (18). In 
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this respect, the recent finding of multidrug transporters, such as P-glycoprotein 
and multidrug resistance-associated protein which are in the endothelial cells of 
the BBB, is of particular interest, since these outwardly directed active efflux 
mechanisms appear to act as an active defense mechanism, limiting brain 
accumulation of many lipophilic drugs (16; 19; 20).  
 
1.3.2 Role of P-glycoprotein  
   
 
Figure 1.1  Schematic of role of P-gp in the blood-brain barrier and central 
nervous system.(Left) Passive diffusion of P-gp substrate from blood into brain 
capillary endothelial cell, which may then (middle, 1a) passively diffuse across 
the endothelial cell to interstitial fluid, or (middle, 1b) be actively transported 
from capillary endothelial cell back into capillary lumen (blood) by P-gp. (Right) 
Interaction of glial cell-associated P-gp with substrate. 
 
P-glycoprotein (P-gp), a transmembrane glycoprotein active efflux system 
 9 
discovered in 1976, consists of a group of closely related, intrinsic membrane 
proteins encoded by a small family of genes (21). The P-gp isoforms involved 
in multidrug resistance are encoded by the MDR1 gene in humans and the 
mdr1a or mdr1b genes in rodents. Tishler et al (22) were the first to discover 
that the MDR1 gene is overexpressed in astrocytes and capillary endothelial 
cells in the brains of patients with intractable epilepsy. Since P-gp can actively 
transport a huge variety of hydrophobic and amphipathic drugs out of the cell 
(23) and most drugs that are good P-gp substrates have a molecular weight 
(MW) above 400 Da, such as domperidone (MW 426), loperamide (MW 477), 
doxorubicin (MW 544), nelfinavir (MW 568)，indinavir (MW 614) and digoxin 
(MW 781) (24). It has been hypothesized that P-gp might be responsible for the 
very poor penetration of many relatively large (>400 Da) lipophilic drugs in the 
brain, by performing active back-transport of these drugs to the blood. 
Extensive experiments with in vitro models and knockout mice lacking BBB 
P-gp or other animal models treated with blockers of P-gp have fully proved 
this hypothesis (15; 16). Absence of functional P-gp in the blood–brain barrier 
leads to highly increased brain penetration of a number of important drugs. The 
anticancer drug vinblastine accumulated 20-fold more in brain of mdr1a 
knockout mice, whereas the corresponding plasma level was only 2-fold 
increased in mdr1a knockout mice (25). The drug digoxin, which has a strong 
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tendency to bind to brain tissue, continued to accumulate in the brain of mdr1a 
knockout mice for a period of 3 days after a single intravenous bolus injection, 
resulting in a 200-fold higher brain level as compared to wild-type mice (26). 
Depending on the pharmacological target of these drugs in the central nervous 
system (CNS), this can result in dramatically increased neurotoxicity, or 
fundamentally altered pharmacological effects of the drug. Given the variety of 
drugs affected by P-gp transport, it may be of tremendous therapeutic value to 
apply these insights into the development of drugs that should have either very 
poor or very good brain penetration, whichever is preferred for 
pharmacotherapeutic purposes. 
 
1.3.3 Role of MRP 
 
The first member of the MRP family, MRP1, was discovered in cancer cells in 
1992. MRP has seven members (MRP1–7). Apart from cancer cells, MRPs are 
also located in several normal tissues, including the BBB and blood-CSF barrier. 
They act as organic anion transporters, but can also transport neutral organic 
drugs (27). As P-gp and MRPs have overlapping substrate specificity, drugs 
could be the substrates for both P-gp and MRPs (28).  
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1.3.4 Role of multidrug transporters in the AEDs neuropharmacokinetics and 
pharmacoresistence 
 
In addition to modulation on CYP activity, AED interactions may also occur due 
to modulation on multidrug transporters by either induction of the transporter 
activity or competition inhibition by AEDs. An increasing number of in vitro 
studies have been carried out to elucidate the mechanism. Meanwhile, 
increasing in vivo studies were performed to obtain the most direct evidence.  
 
Recent studies have demonstrated overexpression of multidrug transporters in 
the epileptic focus tissue obtained during surgery from patients with 
drug-refractory partial epilepsy (29). Based on these data, enhanced P-gp 
overexpression is hypothesized as a basic mechanism of pharmacoresistance in 
epileptic patients, which constitute of 20-30% of the whole patient population. 
The majority of these pharmacoresistant patients do not respond to a variety of 
antiepileptic drugs with different mechanisms of action (30). This indicates the 
involvement of unspecific mechanisms such as limitation of AED access to the 
epileptic focus region by overexpressed multidrug transporters. 
 
There is accumulating evidence from studies in animal models and preliminary 
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studies in humans that P-gp has a significant role in limiting substrate 
penetration into CNS and is an important determinant of pharmacologic effect 
and toxicity within the CNS (31). 
 
In addition, previous research has shown that gabapentin, topiramate, phenytoin, 
carbamazepine, phenobarbital, felbamate and lamotrigine are the substates of 
P-gp. But only valproate, phenytoin and carbamazepine have been found to be 
the substrates of MRP (28).  
 
Based on the above knowledge, we hypothesize that co-administration of AED 
will cause AED drug interactions by interference with drug transporter system 
as well as metabolic enzymes. In this regard, we designed in vivo studies to 
verify our hypothesis. 
 
1.4 Experimental models in neuropharmacokinetic studies 
  
1.4.1 In vivo and in vitro methods 
 
To investigate the neuropharmacokinetics of AEDs, an in vivo method is 
necessary to simulate the situation of drug transport into the brain. Several in 
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vivo experimental approaches have been developed to quantify the transport of 
compounds from blood to brain, like brain homogenization (32), CSF sampling 
(33), quantitative autoradiography (34) and nuclear magnetic resonance (NMR) 
(35). Among these methods, microdialysis system has been suggested and 
practiced widely to determine drug concentrations in rat brains as it determines 
the local extracellular concentrations of a free drug as a function of time in 
individual freely moving animals.  
 
In addition to in vivo models, cultured endothelial cells provide a more direct in 
vitro model to investigate the transport and uptake profile of AEDs. However, 
despite the physiological variations existing between different passages, the 
cultured cell model can not simulate the complicity as in vivo situation. Some 
other cell models such as Caco-2 cell monolayers have also been suggested as 
an in vitro model to investigate the effect of P-gp on drug transport (36). 
Unfortunately, as such cell line is not derived from the brain, the discrepancy in 
explaining the experiment results are not avoidable. 
 
In this project, the specific AED interaction will be investigated in vivo using 
microdialysis technique on rat models. 
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1.4.2   Microdislysis technique 
 
Microdialysis involves the insertion of a microdialysis probe into a selected 
tissue or body fluid. The probe consists of a small semipermeable hollow fiber 
membrane, connected to an inlet and outlet tubing with a small diameter. The 
probe is continuously perfused with a physiological solution, the perfusate. The 
perfusate is an aqueous solution that must closely match the ionic composition 
of the extracellular fluid surrounding the probe in order to prevent unwanted 
changes in composition of periprobe fluid due to drainage or introduction of 
molecules. Molecules able to pass the semipermeable membrane will diffuse 
over the membrane down their concentration gradient into or out of the 
perfusate. The solution that exits the probe, the dialysate, can be collected for 
analysis. The concentration of the drug in the dialysate reflects the 
concentration in the extracellular fluid around the semipermeable part of the 
probe (37).   
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Figure 1.2 Experimental design of microdialysis 
 
The technique of microdialysis has enabled the temporal measurement of brain 
extracellular fluid (bECF) drug concentrations in discrete brain areas following 
a peripheral administration. This technique has a temporal and spatial resolution 
suitable for the study of a drug’s neuropharmacokinetics without a significant 
perturbation to the system measured. Importantly, the blood brain barrier is 
intact shortly after the slow implantation of microdialysis probes. The 
concentration of unbound drug in the brain can be measured continuously over 
time within one animal and can be compared with the blood concentration-time 
profile. Previously, brain drug concentration-time profiles have been determined 
in many animals at different time-points after drug administration using the 
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technique of brain homogenization. And unlike quantitative autoradiography, 
microdialysis can differentiate between parent drug and metabolites or between 
bound and free drug concentrations (38). Before microdialysis technique was 
available, the concentration of drug in CSF was used as a surrogate of the 
concentration of unbound drug at the site of action in brain. However, transport 
of the drug across the blood-brain barrier and blood-CSF barriers may differ, 
and CSF concentrations may not be representatives of brain CSF concentrations 
(39). Further advantage of the microdialysis technique is that it is possible to 
study drug interactions at the BBB, including the influence of active efflux 
mechanisms and the impact of blocking these mechanisms by microdialysis 
because cross-over studies can be performed within one animal over at least two 
to seven days. Microdialysis also enables simultaneous measurements in two or 






























To have a better understanding of in vivo drug interactions in AED polytherapy, 
we hypothesized that neuropharmacokinetic interactions of AEDs may occur 
during co-administration of AEDs given in a single dose or multiple dosing. 
Such interactions may be contributed by inhibition or induction of the activity 
of drug transporters or metabolic enzymes located in the BBB or in brain. 
However, we realize that conventional pharmacokinetic studies may not be very 
effective in determination of such neuropharmacokinetic interactions and 
neuropharmacokinetic interactions may not necessarily reflect the 
pharmacokinetic interactions in the plasma. 
 
First of all, although plasma concentration monitoring of AEDs is widely and 
effectively used in the management of patients, its primary aim is to serve as an 
index of brain concentrations (i.e. the concentration at the site of action). 
Unfortunately, quite often, plasma pharmacokinetics may be a very poor index 
of neuropharmacokinetics following acute administration of AEDs, such as 
phenytoin, when used for the treatment of status epilepticus (41). An 
understanding of the neuropharmacokinetics of such drugs is critical for: 
optimization of therapy, determination of the value of plasma concentration 
monitoring, and ascertaining drug modes and mechanisms of action. 
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Secondly it is not enough to picture the brain as a single compartment. The 
brain consists of extracellular, intracellular, and cerebrospinal fluid (CSF) 
compartments and which compartment’s kinetics is of most relevance depends 
upon where the site of action is. The constitution of as well as the access to, 
these compartments, is different. The pharmacokinetics of AEDs in whole brain 
is determined by non-specific binding to brain lipids and proteins; they are thus 
unlikely to present the pharmacokinetically relevant compartment. Receptors on 
neurons, and ion channels on axons are surrounded by bECF, and it is likely that 
the drugs act on these receptors and ion channels and their action will be 
determined by the unbound concentration of drugs in the bECF. Although the 
bECF and CSF are produced independently, they are in direct communication 
with one another so that changes in the composition of one often reflected the 
changes in the composition of the other (42). CSF drug concentrations could 
thus be an indirect index of bECF concentrations. Measurements of CSF 
penetration, however, do not necessarily give an accurate indication of blood 
brain permeability. A study of 2’,3’-didehydro-3’-deoxythymidine (D4T, an 
anti-HIV drug) on guinea-pigs indicated that [3H]-D4T had a limited ability to 
cross the blood-brain barrier (BBB), which was not significantly greater than 
D-[14C]-mannitol (a slowly penetrating marker molecule). Although D4T was 
found to cross the blood-CSF barrier, the presence of D4T in the CSF did not 
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reflect levels of the drug in the brain tissue (43).  
 
Due to the insufficient studies in the neuropharmacokinetic interactions between 
AEDs, only limited quantitative information is available about the relationship 
between the pharmacokinetics and neuropharmacokinetics of AEDs despite a 
large number of patients in clinic. In dearth of such information, it is necessary 
to establish the neuropharmacokinetic profiles of commonly used AEDs. 
 
The objective of the present study is to establish the neuropharmacokinetic 
profiles of AEDs using in vivo rat models. To achieve such objective, the 
following specific experiments were performed: 
1. To establish a in vivo neuropharmacokinetic model in rats by microdialysis 
technique. 
2. To establish analysis method for AEDs using HPLC and/or LC-MS/MS 
instruments. 
3. To establish the pharmacokinetic and neuropharmacokinetic profiles of the 
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Phenytoin (PHT) is one of the most widely used antiseizure agents. It is 
effective against partial and tonic-clonic but not absence seizures. It has been 
thoroughly studied in the laboratory and in clinical practice more than any other 
antiseizure drugs. Neuropharmacokinetic interactions between PHT and other 
anti-epilepsy drugs may occur as more and more evidence suggested the 
involvement of drug transporters in PHT disposition to the brain. 
 
The first in vivo study on the impact of P-gp on the brain uptake of PHT was 
carried out using mdr1a/b knockout mice. In this study, a modest increase of 
PHT levels in brain was found in mdr1a/b knockout mice as compared to 
control mice (44). Subsequent studies utilizing microdialysis technique 
indicated that the uptake of PHT into rat brains was enhanced by the 
administration of any of the three P-gp inhibitors, cyanide, verapamil or 
PSC833 (45).  
 
Besides the above studies on the role of P-gp in the uptake of PHT into brain, 
several different strategies were also used to study the contribution of MRP2 to 
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phenytoin disposition into the brain. Increased brain extracellular levels of 
phenytoin was found in rats after co-administration of the MRP2 inhibitor 
probenecid, which indicate that phenytoin may be a substrate of MRP2 and its 
disposition was therefore influenced by MRP2 expressed in the BBB (46). This 
was substantiated by using MRP2-deficient TR– rats (46), in which extracellular 
brain levels of phenytoin were significantly increased compared to the normal 
background strain. In the kindling model of epilepsy, coadministration of 
probenecid significantly increased the anticonvulsant activity of phenytoin. In 
kindled MRP2-deficient rats, phenytoin exerted a markedly higher 
anticonvulsant activity than in normal rats. These data indicate that MRP2 
substantially contributes to the transport of phenytoin into brain (46).  
 
In vitro studies further provided more direct evidence on interactions between 
drug transporters and PHT. In a study using cultured rat astrocytes, PHT and 
another anti-epilepsy drug carbamazepine induced the overexpression of P-gp in 
astrocytes in a dose- and time-dependent manner. By immunocytochemistry 
staining, significantly higher levels of P-gp were detected at therapeutic 
concentration of PHT (20 μg/ml phenytoin) (47). In another studies involving 
MDR1 transfected cell, however, the author did not expect severe drug-drug 
interactions to happen in clinical due to the dose limitation in real practice even 
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though they found inhibition effect of PHT on P-gp activity (48).  
 
Felbamate 
Felbamate (FBM) is approved by FDA in 1993 as an adjunct therapy or 
monotherapy in the treatment of partial seizures in adults, with and without 
secondary generalization, and as adjunct therapy in the partial and generalized 
seizures associated with Lennox-Gastaut syndrome in children (49). FBM is 
chemically unique compared with other anticonvulsants and it possesses activity 
in nearly all major seizure types. In vitro studies show that FBM is a substrate 
for CYP3A4 and CYP2E1 (50). Compounds which induce CYP3A4 (eg 
carbamazepine, PHT and phenobarbital) increase FBM clearance. Interestingly, 
the CYP3A4 inhibitors gestodene, ethinyl estradiol and erythromycin have little 
or no effect on FBM plasma concentrations (50). The findings indicate that 
FBM is only slightly, if any, metabolized by CYP3A4 under normal conditions. 
 
PHT-FBM interactions 
PHT may result in the most unpredictable consequences in clinical application 
because of its low therapeutic index and dose-dependent nonlinear 
pharmacokinetics. A clinical study (51) has been carried out to investigate the 
pharmacokinetic interaction of FBM and PHT and it showed that PHT plasma 
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concentrations increase 25-35% with FBM coadministration because FBM 
inhibits CYP2C19, one of the cytochrome P450 isoforms, which is responsible 
for the metabolism of PHT. On the contrary, the Cmax value of FBM in plasma is 
reduced by about 60% because PHT is the inducer of CYP3A4 which is 
responsible for the biotransformation of FBM.  
 
Besides clinical data, interaction of FBM with PHT was also investigated in 
maximal electroshock mice. A combination of FBM with nonprotective doses of 
PHT (3 and 6 mg/kg), valproate (100 and 150 mg/kg), carbamazepine (2 and 4 
mg/kg) and phenobarbital (2 and 4 mg/kg) produced a synergistic and potent 
anticonvulsant action as compared with FBM alone against maximal 
electroshock mice (52). For example, PHT (3 and 6 mg/kg) administered before 
maximal electroshock increased FBM protection by 30 and 60%, respectively as 
measured by a reduction of ED50. It has been thought that the increase was due 
to a pharmacodynamic interaction but not a pharmacokinetic interaction 
because there was no significant FBM change in plasma after coadministrations 
and the FBM plasma concentrations were well below the effective plasma 
concentration when FBM was administered alone. The fact is that the plasma 
concentration is only a surrogate of FBM concentration at the site of action in 
brain and it is not clear whether there is any change in bECF concentration of 
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FBM in the presence of PHT. Though there is no direct in vivo evidence now, 
the interaction of FBM and/or PHT with drug protein transporters such as P-gp 
and MRP2 is also a possible mechanism for the synergistic anticonvulsant effect. 
Further in vivo study is thus needed to investigate possible 




3.2.1 Chemicals and Reagents 
 
FBM was obtained as a free sample from Carter-Wallace Inc.. 
5,5-Diphenyl-2,4-imidazolidinedione (PHT) and its main metabolite 
5-(4-Hydroxyphenyl)-5-phenylhydantoin (HPPH) were obtained from 
Sigma-Aldrich (Singapore). Acetonitrile and methanol (HPLC grade) was 
purchased from Mallinckrodt Baker, Inc (Paris, Kentucky). Methanol, 
phosphoric acid and hydrochloride (37%), all of analytical reagent grade, were 
obtained from Lab-Scan Analytical Science (Dublin, Ireland). Ketamine was 
from obtained from Laboratory Animal Centre, National University of 







The HPLC analysis was performed on a Shimadzu LC-10AT gradient liquid 
chromatography pump connected to a Shimadzu SPD-10AVP detector set at a 
wavelength of 210 nm. (Shimadzu Corporation, Japan). A Waters XTerra® 
Phenyl 5 μm column (4.6 x 150 mm) (Waters Corporation, Milford, 
Massachusetts), with a guard column, was used to analyze PHT or FBM in 
plasma and bECF. 
 
3.2.2.2 Microdialysis and jugular vein cannulation 
 
Microdialysis sampling was performed using a CMA/12 microdialysis probe 
obtained from CMA microdialysis Company (Swede, 2 mm polycarbonate 
membrane, cut-off 20 kDa). A CMA/120 syringe pump (CMA microdialysis 
Company, Swede) coupled to a 1.0 ml syringe was used for the delivery of 
artificial cerebrospinal fluid (aCSF, in mM: 145 NaCl, 1.2 CaCl2, 2.7 KCl and 
1.0 MgCl2, 2.0 Na2HPO4, pH 7.4) at a flow rate of 2 µl/min. bECF samples 
were collected by a CMA/170 refrigerated fraction collector (CMA 
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microdialysis Company,Swede). A CMA/130 in vitro stand (CMA microdialysis 
Company, Swede) was used in the determination of in vitro recovery. Guide 
cannulae (CMA/12 polyurethane, CMA microdialysis Company, Sweden). 
Catheter (PE 50 polyethylene tubing, 10 cm long, o.d. 0.965mm , i.d. 0.58 mm; 




3.3.1 HPLC and LC-MS/MS method validation 
 
3.3.1.1 HPLC assay for PHT in rat plasma and bECF 
 
The high performance liquid chromatography with UV detector was used for 
the determination of PHT in plasma at high dose level and low dose level as 
well as PHT in bECF at high dose level. This method was a modification of the 
method of Tanaka et al (53). The mobile phase consisted of methanol – borate 
buffer (40: 60). The pH of 100 μM borate buffer was adjusted to 9.1 by KOH 
solution. Sample injection loop was 20 μl. The mobile phase was filtered with a 
0.20 μm filter membrane (Nylon, 47mm, phenomenex, USA) prior to its use. 
The pump was set at a flow rate of 0.8 ml/min. The peak was detected at the 
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wavelength of 210 nm.  
 
3.3.1.1.1 Standard stock solution, calibration and quality control samples 
 
Stock solution of PHT was prepared by dissolving weighed amount of PHT in 
MeOH to obtain a concentration of 1000 µg/ml. Working solution was prepared 
by mixing the stock solution with methanol or aCSF for calibrations in the 
plasma and bECF, respectively, to final concentrations. The calibration 
standards were freshly prepared everyday by diluting the working solutions 
with the plasma or aCSF to the following concentrations: 42.000, 21.000, 
10.500, 4.200, 2.100, 0.840 and 0.168 µg/ml for PHT in plasma; 0.017, 0.034, 
0.068, 0.136, 0.272, 0.544 and 1.088 µg/ml for PHT in aCSF. For the quality 
control (QC) sample, the following concentrations were chosen: 42.000, 4.200 
and 0.168 µg/ml for plasma samples whereas 1.088, 0.136 and 0.017 µg/ml for 
aCSF samples. All the stock solutions and QC samples were protected from 
light and stored at –20 °C. 
 
3.3.1.1.2 Plasma sample processing 
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Plasma sample preparation involved a single protein precipitation step. A 50 µl 
aliquot of plasma sample was pipetted into a 1.5-ml polypropylene Eppendorf 
micro test tube, followed by 50 µl acetonitrile. The tube was vigorously mixed 
for 60 s and centrifuged for 10 min at 5000 rpm. The supernatant was 
transferred into another 1.5-ml polypropylene Eppendorf micro test tube, and an 
aliquot (20 µl) was injected directly into the HPLC system. 
 
3.3.1.1.3 Assay validation 
3.3.1.1.3.1 Linearity 
The linearity of the method was evaluated using the calibration standards in the 
range of 0.168 – 42.000 µg/ml for plasma and 0.017 – 1.088 µg/ml for aCSF.  
3.3.1.1.3.2 Within-day and between day accuracy and precision 
Within-day and between-day accuracy and precision of the assay were assessed 
by performing replicate analyses of three QC sample concentrations (42.000, 
4.200 and 0.168 µg/ml for plasma samples whereas 1.088, 0.136 and 0.017 
µg/ml for aCSF samples). The procedure was repeated on 5 different days on 
the spiked standards to determine between-day repeatability. With-day 




The absolute recovery was determined by comparing peak areas from drug free 
plasma spiked with known amounts of drugs, with peak areas of the same 
concentrations prepared in acetonitrile and injected directly onto an analytical 
column. The recoveries were examined using the QC standards. Each sample 
was determined in triplicate. 
3.3.1.1.3.4. The limit of quantitation 
The limit of quantitation (LOQ) was defined as the lowest concentration level 
for which the intra- and inter-day coefficient of variation is no greater than 20% 
 
3.3.1.2 LC-MS/MS assay for PHT and HPPH in bECF 
 
This LC-MS/MS method was used for the determination of PHT and HPPH in 
bECF at low dose level. 
 
3.3.1.2.1 Mass spectrometry and HPLC conditions 
 
The LC-MS/MS system consisted of an Agilent 1100 series liquid 
chromatography (including an Agilent 1100 LC Binary Pump and an Agilent 
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1100 G1367A autosampler) coupled to an Applied Biosystems QTrap mass 
spectrometer equipped with a Turbo IonSpray interface. The negative ion mode 
was performed. The MS/MS conditions were tuned by the continuing infusion 
of drug to the mass system and set as follows. (1) The multiple reaction monitor 
(MRM) mode was set at 253.0→102.0 m/z for PHT, 267.0→118.0 m/z for 
HPPH. (2) Nebulizer gas (Gas 1) was set as 60; auxiliary gas (Gas2) was set as 
30; temperature of the turbo gas was set as 150 ºC; interface heater was set off; 
curtain gas was set as 10; ion spray voltage was -4500 V; CAD was set as low; 
and collision energy was set as -33.00 eV. (3) Declustering potential: -190 V; 
entrance potential: -11 V; cell entrance potential:  -23.3 V; and cell exit 
potential: -2.40 V were set for both PHT and HPPH.  
 
A reversed-phase C18 column (5 μm, 150 mm×2.0 mm i.d.) was used. The 
mobile phase consisted of acetonitrile–10 mM ammonium acetate buffer (50:50, 
v/v) at the flow rate of 0.2 ml/min. Peak detection was carried out on a Linear 
Ion Trap Quadrupole LC/MS/MS Mass Spectrometer (AB Sciex Instruments) 
using Turbo Spray negative mode.  
 
3.3.1.2.2 Standard stock solution, calibration and quality control samples 
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Stock solution of PHT or HPPH was prepared by dissolving weighed amount of 
PHT or HPPH in MeOH to obtain a concentration of 1000 µg/ml. Working 
solution was prepared by mixing the stock solution with aCSF to final 
concentrations. For the standard curve, the final concentrations of PHT in aCSF 
were as follows: 380, 190, 76, 38, 9.5, 3.8 and 1.9 ng/ml; the final 
concentrations of HPPH in aCSF were as follows: 380, 190, 76, 38, 9.5, 3.8 and 
1.9 ng/ml. The calibration standards were freshly prepared on each analysis day 
by diluting the working solutions with aCSF to appropriate concentrations. For 
the quality control (QC) sample, the concentrations were 380, 38 and 1.9ng/ml 
for PHT and 380, 38 and 1.9 ng/ml for HPPH. All the stock solutions and QC 
samples are protected from light and stored at –20 °C. 
 
3.3.1.2.3 Assay validation 
 
The linearity, within-day and between day accuracy, absolute recovery and the 
limit of quantitation were determined using the calibration standards and QC 




3.3.1.3. HPLC assay for FBM in plasma and bECF 
 
The high performance liquid chromatography with UV detector was used for 
the determination of FBM in plasma at high dose level and low dose level as 
well as FBM in bECF at high dose level. This method was a modification of the 
method of Gur et al (54). The mobile phase for the separation of FBM consisted 
of acetonitrile – phosphate buffer (15: 85). The pH of 100 μM phosphate buffer 
was adjusted to 6.8. Sample injection loop was 20 μl. The mobile phase was 
filtered with a 0.20 μm filter membrane (Nylon, 47mm, phenomenex, USA) 
prior to its use. The pump was set at a flow rate of 0.8 ml/min. The peak was 
detected at the wavelength of 210 nm.  
 
3.3.1.3.1 Standard stock solution, calibration and quality control samples 
 
Stock solution of FBM was prepared by dissolving weighed amount of FBM to 
obtain a concentration of 1000 µg/ml. Working solution was prepared by mixing 
the stock solution with methanol or aCSF to final concentrations. The 
calibration standards were freshly prepared everyday by diluting the working 
solutions with plasma or aCSF to the following concentrations: 85.600, 42.800, 
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21.400, 8.560, 4.280, 1.712, and 0.342 µg/ml for plasma samples; 0.043, 0.086, 
0.172, 0. 344, 0.688, 1.376 and 2.752 µg/ml for aCSF samples. For the quality 
control (QC) sample, the following concentrations were chosen: 85.600, 8.560 
and 0.342 µg/ml for plasma samples; 2.752, 0.344 and 0.043 µg/ml for aCSF 
samples. All the stock solutions and QC samples were protected from light and 
stored at –20 °C prior to their use. 
 
3.3.1.3.2 Plasma sample processing and assay validation 
 
Rat plasma samples were processed following the same protocol as for PHT. 
The assay was validated using the calibration standards and QC standards 
following the same protocol as for PHT. 
 
3.3.1.4 LC-MS/MS assay for FBM in bECF 
 
This LC-MS/MS method was used for the determination of FBM in bECF at 
low dose level. 
 
3.3.1.4.1 Mass spectrometry and HPLC conditions 
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The LC-MS/MS system consisted of an Agilent 1100 series liquid 
chromatograph (including an Agilent 1100 LC Binary Pump and an Agilent 
1100 G1367A autosampler) coupled to an Applied Biosystems QTrap mass 
spectrometer equipped with a Turbo IonSpray interface. The positive ion mode 
was performed. The MS/MS conditions were tuned by the continuing infusion 
of drug to the mass system and set as follows. (1) The multiple reaction monitor 
(MRM) mode was set at 239.10→117.10 m/z for FBM. (2) Nebulizer gas (Gas 
1) was set as 60; auxiliary gas (Gas2) was set as 70; temperature of the turbo 
gas was set as 200 ºC; interface heater is set off; curtain gas is set as 20; Ion 
spray voltage is 3000 V; CAD is set as low; and collision energy was set as 
25.00 eV. (3) Other settings included declustering potential: 145 V; entrance 
potential: 11 V; cell entrance potential: 22.71 V; and cell exit potential: 2.8 V.   
 
A reversed-phase C18 column (5 μm, 150 mm×2.0 mm i.d.) was used. The 
mobile phase consisted of acetonitrile–10 mM ammonium acetate buffer (30:70, 
v/v) at the flow rate of 0.2 ml/min.  
 
3.3.1.4.2 Standard stock solution, calibration and quality control samples 
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Stock solution of FBM was prepared by dissolving weighed amount of FBM in 
MeOH to obtain a concentration of 100 µg/ml. Working solution was prepared 
by mixing the stock solution with methanol to final concentrations. For the 
standard curve, the final concentrations of FBM in aCSF were as follows: 470, 
188, 94, 47, 18.8, 9.4, 4.7, 2.35 and 1.175 ng/ml. The calibration standards were 
freshly prepared on each analysis day by diluting the working solutions with 
aCSF to appropriate concentrations. For the quality control (QC) sample, the 
concentrations of FBM in medium were 470, 18.8 and 1.175 ng/ml. All the 
stock solutions and QC samples were protected from light and stored at –20 °C. 
 
3.3.1.4.3. Assay validation 
 
The assay was validated using the calibration standards and QC standards 
following the same protocol as for PHT. 
 





Male Sprague Dawley rats (body weight 250-300 g) were purchased from the 
Laboratory Animal Centre of the National University of Singapore. They were 
randomly assigned into three groups with two in each group. All studies were 
conducted in accordance with the National University of Singapore guidelines 
for the care and use of laboratory animals. 
 
3.3.2.2 Drug administration 
 
The three-period, three- sequence crossover experimental design was employed 
for each of low and high doses in the study. The rats in each group received 
either PHT alone, FBM alone or the compbined PHT and FBM on different 
occasions with a wash-out period of three weeks between the treatments as 
shown in Table 3.1 (A). A shorter wash-out period of a week was used for the 
low dose level as shown in Table 3.1 (B). The body weight of the rat was 







Table 3.1 (A) PHT and FBM administration scheme to rats at high dose level 
 1# (Day 1) 2# (Day 21) 3# (Day 42) 
Rat 1 FBM PHT+FBM PHT 
Rat 2 FBM PHT+FBM PHT 
Rat 3 PHT+FBM PHT FBM 
Rat 4 PHT+FBM PHT FBM 
Rat 5 PHT FBM PHT+FBM 
Rat 6 PHT FBM PHT+FBM 
 
Table 3.1 (B) PHT and FBM administration scheme to rats at low dose level 
 1# (Day 1) 2# (Day 8) 3# (Day 15) 
Rat 1 FBM PHT+FBM PHT 
Rat 2 FBM PHT+FBM PHT 
Rat 3 PHT+FBM PHT FBM 
Rat 4 PHT+FBM PHT FBM 
Rat 5 PHT FBM PHT+FBM 
Rat 6 PHT FBM PHT+FBM 
 
3.3.2.3 Microdialysis experiments 
 
3.3.2.3.1 In vitro recovery of microdialysis probe for PHT and FBM  
 
FBM and PHT were dissolved in aCSF in a micro-Eppendorf tube, with the 
concentrations of 4.0 μg/ml and 2.0 μg/ml, respectively, and a final volume of 
 40 
1.5 ml was achieved. The microdialysis probe was immersed into aCSF and the 
perfusion of the FBM and PHT mixture was started by a CMA/100 
microinjection pump with the flow rate of 2 μl/min. The dialysate sample was 
subsequently collected by a CMA/170 refrigerated fraction collector every 20 
minutes. A total of 4 dialysate samples were collected and directly subject to the 
HPLC assay. Another two parallel experiments were performed with the 
respective concentration of 0.5 μg/ml for FMB and 0. 1 μg/ml for PHT as well 
as 0.05 μg/ml for FMB and 0. 01 μg/ml for PHT . 
 
3.3.2.3.2 Microdialysis and jugular vein cannulation surgery procedure 
 
Under anesthesia with ketamine (100 mg/kg, i.p.), the rat was implanted with 
the guide cannulae into the left or right frontal (motor) cortex. This implantation 
site was chosen for high expression level of brain P-gp as demonstrated by the 
immunohistological experiments as well as technical reasons of microdialysis 
experiments on rats (55). The tips of the guide cannulae are positioned at –2.7 
mm bregma, +1.2 ventral and ± 2.9 mm lateral by following the atlas by 
Paxinos and Watson (56). The cannula was fixed with additional anchor screws 
and dental acrylic cement, which was applied to the exposed skull surface. After 
surgery, rats were housed individually.     
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Following a recovery period of at least 2 days after surgery, a catheter was 
implanted in the external jugular vein for blood sampling. The rat was placed on 
its back, and its forelegs were affixed to a surgical board with adhesive tape. A 
2.5 cm long incision in the skin was made in the midline between the collar 
bone and the sternal bone, and the external jugular vein was exposed by blunt 
dissection. After removing the tissue surrounding the vein with a pair of 
tweezers, three cotton threads were passed under the vein caudally, medially, 
and rostrally, and the caudal thread was ligated. Using a pair of fine scissors, the 
vein was just perforated below the medial thread, dilated by inserting a pair fine 
tweezers, and the catheter was inserted until 3 cm of which was within the vein. 
The two other threads were used to secure the positioning of the exteriorized 
portion of the catheter. A 1-cm cut was made behind the ear, a small pair of 
forceps was passed under the skin through the incision, the free end of the 
catheter was brought out behind the ear, and the incision was secured. Catheter 
patency was checked by flushing with 0.3 ml heparinized saline (10 U /ml). A 
length of 3 cm of the catheter was exposed outside of the body and the catheter 
opening was sealed using a piece of 1 -cm tubing made from a 21-G needle, and 
the rat was sutured. After surgery, rats were housed individually (57).  
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3.3.2.3.3 bECF and blood sampling 
 
Following a second recovery period of 3 days after cannulation surgery, a 
microdialysis probe (CMA/12, 2 mm polycarbonate membrane, cut-off 20 kDa; 
Swede) was inserted through the guide cannula to a depth of 3.2 mm according 
to bregma, and the rat was placed in a freely moving system, consisting of a 
plastic cylinder with counter-balancing arm carrying a two-channel swivel 
(CMA, Swede). Fourteen to sixteen hours after insertion, perfusion of the probe 
was started using aCSF solution (in mM: 145 NaCl, 1.2 CaCl2, 2.7 KCl and 1.0 
MgCl2, 2.0 Na2HPO4, pH 7.4). PHT was dissolved in saline by means of NaOH, 
pH 11.0 and FBM was dissolved in 30% PEG 400. A mixure of the two drug 
solutions was also prepared. The high dose investigated was 50 mg/kg for both 
drugs while the low dose used was 6 mg/kg for PHT and 10 mg/kg for FBM, 
with the injection volume of 3 ml/kg for all substances. 
 
Prior to the injection of PHT, FBM or their combination, a 200 μl of blank 
blood sample was drawn for baseline evaluation. Three blank dialysate samples 
were also collected over a time period of 1h before the injection. Afterwards, 
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the rat was subject to intra-peritoneal (i.p.) injection of the drug. After elution 
for dead space, dialysate samples were collected every 20 minutes (40 μl) for 
480 minutes. The inflow to the probe was driven by a CMA/100 microinjection 
pump, and each 40 μl outflow sample was collected with a 250 μl propylene 
tube. The flow rate was 2 μl/min. During the time for dialysate sample 
collection, a serial of venous blood samples (100 μl) was collected at 10, 20, 40, 
60, 90, 120, 150, 180, 210, 240, 300 and 480 min.  
 
The dialysate samples collected were directly subject to the HPLC or 
LC-MS/MS assay. Plasma samples are subject to appropriate extraction 
procedure prior to the HPLC or LC-MS/MS assay. Six rats were used for each 
dose tested. 
 
3.3.3 Data Analysis 
 
3.3.3.1 Neuropharmacokinetic and pharmacokinetic analysis 
 
Pharmacokinetic analyses were performed using the WinNonlin iterative 
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curve-fitting program (Standard edition, 2.1, Scientific Consulting Inc., 
Lexington, KY, USA) based on nonlinear regression analysis. The 
neuropharmacokinetics and pharmacokinetics of PHT and FBM were analyzed 
using model-independent noncompartmental analysis. The peak bECF (or 
plasma) concentration (Cmax) and the time of occurrence for peak concentration 
(Tmax) after i.p. administration were obtained by visual inspection of the bECF 
(or plasma) drug concentration-time curve. The area under the bECF (or plasma) 
concentration-time curve (AUC0-t) from time zero to the last measurable time 
point was calculated using the linear trapezoidal rule and the log-linear 
trapezoidal rule for the pre- and post-peak area, respectively. The total area 
under the serum concentration-time curve from time zero to infinity (AUC0-∞) 
was calculated as the sum of AUC0-t and the extrapolated area, which was 
estimated as the last measurable bECF (or plasma) concentration (Cz) divided 
by the terminal rate constant (λz), where λz was estimated using the terminal 
log-linear phase of the drug concentration-time curve. Terminal half-life (t1/2,λz) 
was calculated as 0.693/λz. The apparent plasma clearance for oral dose (CL/F) 
was calculated as dose/AUC0-∞. The mean residence time (MRT0-∞) was 
determined as AUMC0-∞/AUC0-∞. The area under the first moment curve from 
time zero to infinity (AUMC0-∞) was calculated as the sum of AUMC0-480 and 
the extrapolated area, which was estimated as (tz×Cz/λz + Cz/λz2). The volume 
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of distribution during the terminal phase (Vz/F) was estimated as (CL/F) / λz.  
 
3.3.3.2 Statistical analysis 
 
The Statistical Package for the Social Sciences (SPSS 10.0 for windows, SPSS 
Inc., USA) was used for the data analysis. Data were expressed as mean ± 
standard deviation (SD). A least squares linear regression analysis was used for 
the HPLC calibration curves. A General Linear Model Univariate (GLM 
Univariate) method was utilized to analyze the effect of different administration 
period, combined use of AEDs, regimen sequence on neuropharmacokinetic and 





3.4.1 HPLC and LC-MS/MS assay validation 
 
3.4.1.1 HPLC assay for PHT in plasma and bECF 
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Plasma PHT was assayed using a RP-HPLC method. The chromatograms of 








Figure 3.1 Chromatograms of rat plasma sample. A, blank plasma sample; B, 
plasma containing 4.200 μg/ml PHT; C, blank rat bECF sample; D, rat bEFC 
sample containing 0.136 μg/ml PHT. 
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This assay method was robust, with as low intra-day and inter-day variations as 
≤10% for PHT samples (Table 3.2). The assay also showed a good absolute 
recovery of plasma and bECF samples as shown in Table 3.3. The peak area 
showed a good linear relationship (r2=0.9993 and 0.9992) in the concentrations 
ranges investigated. The linear regression equations were obtained as y = 
74013x - 5975 (r2=0.9992) and y = 146013x – 4908 (r2=0.9993) for the linear 
concentration range of 0.168-42.00 µg/ml (plasma) and 0.017-1.088 µg/ml 
(bECF), respectively. LOQ were 0.168 µg/ml and 0.017 µg/ml for plasma and 











Table 3.2 Intra-day and inter-day variation in peak area for PHT plasma and 
bECF samples as detected by the HPLC assay, in the concentration range of 
0.168-42.00 µg/ml and 0.017-1.088 µg/ml, respectively. Data are presented as 










42.000 40.051 9.85 95.36±9.39 
4.200 3.823 7.65 91.02±6.96 
Intra-day 
plasma 
0.168 0.151 10.26 90.13±9.25 
42.000 42.979 3.21 102.33±3.28 
4.200 4.148 5.68 98.77±5.68 
Inter-day 
plasma 
0.168 0.151 8.11 90.12±7.31 
1.088 1.048  2.05 96.33±1.97 
0.136 0.125  8.96 92.08±8.25 
Intra-day 
bECF 
0.017 0.016  10.26 95.36±9.78 
1.088 1.126  8.56 103.51±8.86 
0.136 0.142  4.56 104.32±4.76 
Inter-day 
bECF 






Table 3.3 Absolute recovery for PHT plasma and bECF samples as detected by 




Recovery (%) R.S.D.(%) 
42.000 99.23 7.85 
4.200 98.23 4.23 Plasma 
0.168 103.55 9.55 
1.088 101.8 1.08 
0.136 99.4 2.36 bECF 
0.017 92.8 6.31 
 
3.4.1.2 LC-MS/MS assay for PHT and HPPH in bECF 
 
To explore the LC-MS/MS analysis method for PHT and its metabolite HPPH, 
MS detection methods were firstly established. The respective MS spectrums of 







 -MS2 (252.00) CE (-33): 230 MCA scans from Sample 2 (PHT MS2_2) of PHT 2.wiff (Turbo Spray) Max. 2.0e5 cps.










































 -MS2 (267.30) CE (-33): 321 MCA scans from Sample 3 (HPPH MS2_2) of HPPH.wiff (Turbo Spray) Max. 1.1e6 cps.









































Figure 3.2 MS/MS Spectra and transitions for PHT (A) and HPPH (B). 
The LC-MS/MS assay for PHT and HPPH was subsequently validated using 
aCSF samples. The chromatogram was shown in Figure 3.3. Linear regression 
equations for PHT and HPPH were y=15.9x-33.5, (r2=0.9986) and y=41.8x-54.7 
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(r2=0.9944), respectively. The assay provided a rapid and accurate method to 
detect these two compounds simultaneously and their intra- and inter-day 
variations were summarized in Table 3.6. The absolute recovery was also 









Figure 3.3 LC-MS/MS chromatogram of PHT (9.5 ng/ml) and HPPH (9.5 
ng/ml) obtained in aCSF solution. A, blank rat bECF sample; B, rat bECF 









Table 3.4 Intra-day and inter-day variation in peak area for aCSF samples of 
PHT and HPPH as detected by LC-MS/MS assay. Data are presented as 










380 374.3 4.7 98.5±4.6 
38 36.5 8.6 96.0±8.3 
Intra-day 
PHT 
1.9 2.1 6.7 112.3±7.5 
380 393.3 5.6 103.5±5.8 
38 34.3 2.3 90.2±2.1 
Inter-day 
PHT 
1.9 1.7 7.6 88.2±6.7 
380 358.0 2.5 94.2±2.4 
38 38.9 4.8 102.3±4.9 
Intra-day 
HPPH 
1.9 1.7 9.2 91.3±8.4 
380 358.3 2.3 94.3±2.2 
38 36.7 8.6 96.7±8.3 
Inter-day 
HPPH 







Table 3.5 Absolute recovery for bEFC samples of PHT and HPPH as detected 




Recovery (%) R.S.D.(%) 
380 99.3 2.8 
38 97.2 6.8 PHT 
1.9 96.5 5.4 
380 98.2 1.2 
38 96.8 3.4 HPPH 
1.9 105.4 7.6 
 
3.4.1.3 HPLC assay for FBM in rat plasma and bECF 
 
FBM in plasma and bECF were assayed using a RP-HPLC method. The 





Figure 3.4 Chromatograms of rat plasma sample. A, blank rat plasma sample; B, 
plasma containing 8.56 μg/ml FBM; C, blank rat bECF sample; D, rat bEFC 
sample containing 0.344 μg/ml FBM. 
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This assay method was robust, with as low intra-day and inter-day variations as 
≤10% for FBM samples in the concentration range of 0.342-85.6 µg/ml and 
0.043-2.752 µg/ml, respectively (Table 3.6). The assay also showed a good 
absolute recovery of plasma samples as shown in Table 3.7. The peak area 
showed good linear relationships (r2=0.9991 and 0.9996) and the linear 
regression equation was calculated as y = 23101x + 1488.5 (r2=0.9991) and y = 
47236x + 2563 (r2=0.9996) for the two concentration ranges. LOQ were 0.342 












Table 3.6 Intra-day and inter-day variation in peak area for FBM plasma and 
bECF samples in the concentration range of 0.342-85.600 µg/ml and 
0.043-2.752 µg/ml, respectively. Data are presented as percentages of RSD and 










85.600 85.283  0.95 99.63±0.95 
8.560 7.906  8.96 92.36±8.28 
Intra-day 
plasma 
0.342 0.360  6.32 105.36±6.66 
85.600 79.060  5.69 92.36±5.26 
8.560 9.101  1.22 106.32±1.30 
Inter-day 
plasma 
0.342 0.338  4.69 98.78±4.63 
2.752 2.541  2.88 92.35±2.66 
0.344 0.332  8.56 96.44±8.26 
Intra-day 
bECF 
0.043 0.042  6.32 97.25±6.15 
2.752 2.651  7.69 96.32±7.41 
0.344 0.317  4.39 92.04±4.04 
Inter-day 
bECF 






Table 3.7 Absolute recovery for FBM plasma and bECF samples as detected by 




Recovery (%) R.S.D.(%) 
85.600 99.23 8.92 
8.560 96.78 8.23 Plasma 
0.342 103.65 9.26 
2.752 98.98 8.95 
0.344 99.23 6.32 bECF 
0.043 96.32 4.36 
 
3.4.1.4 LC-MS/MS assay for FBM in rat bECF 
 
To explore the LC-MS/MS analysis method for FBM, MS detection methods 
were firstly established. The respective MS spectrums of the compound were 
shown in Figure 3.5. 
 61 
 +MS2 (239.30) CE (25): 324 MCA scans from Sample 1 (FBM MS2) of FBM .wiff (Turbo Spray) Max. 7.4e5 cps.






























Figure 3.5 MS/MS Spectra and transitions for FBM 
 
The LC-MS/MS analysis method for FBM was subsequently validated using 
aCSF samples. The chromatogram was shown in Figure 3.6. Linear regression 
equations for FBM was y = 145x + 91.8 (r2=0.9994). The assay provided a rapid 
and accurate method to detect the compound and the intra- and inter-day 
variations were summarized in Table 3.8. The absolute recovery was also 
calculated and listed in Table 3.9. The quantitative limitation was 1.18 ng/ml 
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Figure 3.6 LC-MS/MS chromatogram of FBM (2.35 ng/ml) obtained in aCSF 








Table 3.8 Intra-day and inter-day variation in peak area for aCSF samples of 
FBM as detected by LC-MS/MS assay. Data are presented as percentages of 










470.00 467.65 2.0 99.5±2.0 
18.80 17.48 6.8 93.0±6.3 Intra-day 
1.18 1.27 9.7 107.3±10.4 
470.00 442.74 4.1 94.2±3.9 
18.80 17.15 3.8 91.2±3.5 Inter-day 
1.18 1.23 6.3 104.5±6.6 
 




Recovery (%) R.S.D.(%) 
470.00 99.1 4.8 
18.80 94.2 9.8 
1.18 102. 5.6 
 
3.4.2 Animal Studies 
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   3.4.2.1 Rat body weight and microdialysis probe in vitro recovery 
 
The rat body weight for both the high and low dose investigations (Table 3.10 
and 3.11) was monitored throughout the microdialysis experiments. The body 
weight was increased gradually and no significant drop in the body weight was 
found. Different drug administration regimen yielded a comparable weight 
increment. Results of statistical analysis also showed that neuropharmacokinetic 
and pharmacokinetic parameters were not affected by different administration 
periods and regimen sequences. 
 
Table 3.10 The body weight of rats undergone microdialysis. Drug administered 
at the dose of 50 mg/kg for PHT, FBM or their combination was labeled as 
FBM, PHT or FBM+PHT. 
 1# (Day 1) 2# (Day 21) 3# (Day 42) 
Rat 1 256g (FBM) 347g (PHT+FBM) 407g (PHT) 
Rat 2 263g (FBM) 366g (PHT+FBM) 398g (PHT) 
Rat 3 248g (PHT+FBM) 354g (PHT) 397g (FBM) 
Rat 4 240g (PHT+FBM) 329g (PHT) 383g (FBM) 
Rat 5 258g (PHT) 349g (FBM) 403g (PHT+FBM) 




Table 3.11 The body weight of rats undergone microdialysis. Drug administered 
at the dose of 6 mg/kg for PHT, 10 mg/kg for FBM or their combination was 
labeled as FBM, PHT or FBM+PHT. 
 1# (Day 1) 2# (Day 8) 3# (Day 15) 
Rat 1 229g (FBM) 267g (PHT+FBM) 295g (PHT) 
Rat 2 233g (FBM) 258g (PHT+FBM) 298g (PHT) 
Rat 3 236g (PHT+FBM) 259g (PHT) 287g (FBM) 
Rat 4 228g (PHT+FBM) 262g (PHT) 294g (FBM) 
Rat 5 237g (PHT) 271g (FBM) 293g (PHT+FBM) 
Rat 6 236g (PHT) 268g (FBM) 291g (PHT+FBM) 
 
Microdialysis probe in vitro recovery data showed a good consistence with the  
range of drug concentration tested. The mean±SD in vitro relative recovery of 
PHT for the 6 microdialysis probes was 18.1±1.5% (2 μg/mL), 20.4±1.5% (0.1 
μg/mL) and 23.0±1.9% (0.01 μg/mL); that of FBM was 21.4±2.2% (4 μg/mL), 
23.8±1.6% (0.5 μg/mL) and 26.1±1.4% (0.05 μg/mL). An average of these 
recovery values at different concentrations for each drug was then used to 
calculate in vivo concentration data. The following equation was used to 
calculate drug concentrations in bECF: CbECF = Cdial / Rav, where CbECF is drug 
concentrations in bECF, Cdial is the measured drug concentrations in dialysate 
and Rav is the in vitro recovery value of microdialysis probe.  
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3.4.2.2 Neuropharmacokinetic and pharmacokinetic interaction between 
PHT and FBM at a high dose 
 
3.4.2.2.1 PHT neuropharmacokinetics and pharmacokinetics 
 
The mean bECF and plasma concentration-time profiles of the PHT after i.p. 
administration of a single dose of 50 mg/kg in the presence and absence of 
FBM (50 mg/kg) are shown in Figure 3.7. The estimates of 
neuropharmacokinetic and pharmacokinetic parameters were summarized in 
Table 3.12 and Table 3.13, respectively. With regard to those describing 
neuropharmacokinetics, the concomitant i.p. injection of 50 mg/kg FBM 
increased the PHT AUC0-∞ value in bECF significantly (by 119%, p<0.05) (for 
AUC0-480, increased by114%, p<0.05). The bECF Cmax  was increased (by 56%) 
in the combination group compared to the PHT alone group but the difference 
was not statistically significant (0.05<p<0.1). The bECF t1/2, λz, which is a 
neuroPK parameter describing the disposition kinetics in bECF, was not 
significantly affected by adding FBM.  
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With regard to PK parameters, although the co-injection of FBM also increased 
PHT AUC0-∞ in plasma but to a much less extent (by 28%) (for AUC0-480 , 
increased by 17%), the changes were not statistically significant. Most of the 
other PK parameters of PHT were not affected by FBM. 
 
In consideration of bECF PHT bioavailability relative to its plasma 
bioavailability, the PHT AUCbECF/AUCplasma (the ratio between bECF AUC0-∞ 
and plasma AUC0-∞) value of the combination group was found to be 87% 
higher than that of PHT alone group (p<0.01). With respect to plasma t1/2, λz , the 
increase was small (by 6.9%) in the presence of FBM and the difference was 
not statistically significant.     
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PHT bECF time course (Mean ± SD)
Time (min)


























PHT plasma time course (Mean ± SD)
Time (min)



























Figure 3.7 bECF concentration-time profile (A) and plasma concentration-time 
profile (B) of PHT after i.p. administration at a dose of 50 mg/kg PHT in rats 
with (○) or without (●) a concomitant i.p. injection of 50mg/kg FBM. Data 




Table 3.12 Neuropharmacokinetic parameters (mean ± SD) of PHT after i.p. 
administration of 50 mg/kg PHT with or without the concomitant i.p. 
administration of 50 mg/kg FBM in rats. 
NeuroPK parameters PHT (n=6) PHT+FBM (n=6) p-Value 
Cmax (μg/mL) 0.698±0.159 1.090±0.144 0.063 
Tmax (min) 123±29 117±15 0.67 
AUC0-∞ (μg*min/mL) 244.39±84.79 535.52±129.39 0.022 
AUC0-480(μg*min/mL) 171.41±44.18 367.00±64.00 0.034 
λz (min-1) 0.00404±0.00229 0.00419±0.00242 0.409 
t 1/2, λz (min) 224±127 213±106 0.821 
MRT0-∞ (min) 389.35±176.63 417.44±123.03 0.622 
MRT0-480 (min) 218.35±38.30 238.31±9.72 0.192 
AUCbECF/AUCplasma 0.0364±0.0136 0.0679±0.0284 0.000 
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Table 3.13 Pharmacokinetic parameters (mean ± SD) of PHT after i.p. 
administration of 50 mg/kg PHT with or without the concomitant i.p. 
administration of 50 mg/kg FBM in rats. 
PK parameters PHT (n=6) PHT+FBM (n=6) p-Value 
Cmax (μg/mL) 20.560±3.571 24.698±3.018 0.284 
Tmax (min) 30±11 30±17 1.000 
AUC0-∞ (μg*min/mL) 6860.67±1290.31 8787.23±3406.25 0.319 
AUC0-480(μg*min/mL) 5270.27±831.61 6195.70±1347.60 0.388 
λz (min-1) 0.00316±0.00047 0.00312±0.00085 0.882 
t 1/2, λz (min) 223.60±33.34 239±78 0.583 
MRT0-∞ (min) 329.30±56.74 364.50±114.44 0.331 
MRT0-480 (min) 187.40±8.20 189.02±13.24 0.727 
CL/F (mL/min) 2.507±0.751 2.106±0.891 0.442 
Vz/F (mL) 799.15±235.03 662.93±151.49 0.369 
 
 
3.4.2.2.2 FBM neuropharmacokinetics and pharmacokinetics 
 
The mean bECF and plasma concentration-time profiles of the FBM after i.p. 
administration of a single dose of 50 mg/kg in the presence and absence of PHT 
(50 mg/kg) are shown in Figure 3.8. The estimates of neuropharmacokinetic 
and pharmacokinetic parameters were summarized in Table 3.14 and Table 
3.15, respectively. Similar to PHT neuropharmacokinetics, AUC0-∞ and 
AUC0-480 values of FBM in bECF were significantly increased (by 137% and 
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81%, respectively; p<0.05 and p<0.05). There was also an increase (by 28%, 
0.05<p<0.1) for the bECF Cmax value of FBM in the combination group 
compared to FBM alone group. With respect to bECF t1/2, λz , although the 
increase could be found in the average value by 72% in the presence of PHT, 
the difference was not statistically significant. Like PHT, no significant changes 
were observed for FBM pharmacokinetic parameters between the two groups. 
Regarding FBM AUCbECF/AUCplasma value, there was also a significant increase 











FBM bECF time course (Mean ± SD)
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FBM plasma time course (Mean ± SD)
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Figure 3.8 bECF concentration-time profile (A) and plasma concentration-time 
profile (B) of FBM after i.p. administration at a dose of 50 mg/kg in rats with 
(○) or without (●) a concomitant i.p. injection of 50mg/kg PHT. Data were 





Table 3.14 Neuropharmacokinetic parameters (mean±SD) of FBM after i.p. 
administration of 50 mg/kg FBM with or without the concomitant i.p. 
administration of 50 mg/kg PHT in rats. 
NeuroPK parameters FBM (n=6) FBM+PHT (n=6) p-Value 
Cmax (μg/mL) 1.688±0.200 2.162±0.399 0.071 
Tmax (min) 93±21 143.33±32.04 0.041 
AUC0-∞ (μg*min/mL) 401.36±89.25 951.30±448.13 0.045 
AUC0-480(μg*min/mL) 345.37±84.05 625.13±167.63 0.043 
λz (min-1) 0.00479±0.00080 0.00326±0.00120 0.14 
t 1/2, λz (min) 148±26 255±147 0.188 
MRT0-∞ (min) 238.24±38.93 434.11±186.19 0.143 
MRT0-480 (min) 175.42±31.87 231.93±8.42 0.041 









Table 3.15 Pharmacokinetic parameters (mean±SD) of FBM after i.p. 
administration of 50 mg/kg FBM with or with out the concomitant i.p. 
administration of 50 mg/kg PHT in rats. 
PK parameters FBM (n=6) FBM+PHT (n=6) p-Value 
Cmax (μg/mL) 31.061±3.882 29.545±4.545 0.287 
Tmax (min) 115±23 90±27 0.111 
AUC0-∞ (μg*min/mL) 11739.22±3544.06 11599.31±3748.62 0.939 
AUC0-480(μg*min/mL) 8891.10±1363.25 8326.06±2282.51 0.520 
λz (min-1) 0.00349±0.00097 0.00313±0.00088 0.437 
t 1/2, λz (min) 212.48±62.22 235±63 0.508 
MRT0-∞ (min) 334.66±98.02 371.33±82.59 0.519 
MRT0-480 (min) 201.11±18.02 199.87±12.19 0.904 
CL/F (mL/min) 1.510±0.550 1.646±0.849 0.655 
Vz/F (mL) 429.72±75.03 512.22±180.15 0.174 
 
 
3.4.2.3 Neuropharmacokinetic and pharmacokinetic interaction between 
PHT and FBM at a low dose 
 
3.4.2.3.1 PHT neuropharmacokinetics and pharmacokinetics 
 
The mean bECF and plasma concentration-time profiles of the PHT after i.p. 
administration of a single dose of 6 mg/kg in the presence and absence of FBM 
(10 mg/kg) are shown in Figure 3.9. The estimates of neuropharmacokinetic 
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and pharmacokinetic parameters were summarized in Table 3.16 and Table 
3.17, respectively. As shown in Figure 3.9, Table 3.16 and Table 3.17, no 
significant changes were observed for both PHT neuropharmacokinetic and 
pharmacokinetic parameters between the combination group and PHT alone 
group.  
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PHT bECF time course (Mean ± SD)
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PHT plasma time course (Mean ± SD)
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Figure 3.9 bECF concentration-time profile (A) and plasma concentration-time 
profile (B) of PHT after i.p. administration at a dose of 6 mg/ml in rats with (○) 
or without (●) a concomitant i.p. injection of 10 mg/kg FBM. Data were 






Table 3.16 Neuropharmacokinetic parameters (mean±SD) of PHT after i.p. 
administration of 6 mg/kg PHT with or without the concomitant i.p. 
administration of 10 mg/kg FBM in rats 
NeuroPK parameters PHT (n=6) PHT+FBM (n=6) p-Value 
Cmax (μg/mL) 0.0535±0.0125 0.0580±0.0069 0.374 
Tmax (min) 63±15 53±10 0.182 
AUC0-∞ (μg*min/mL) 11.63±3.53 12.14±2.61 0.803 
AUC0-480(μg*min/mL) 9.99±3.38 10.47±2.54 0.812 
λz (min-1) 0.00567±0.00071 0.00570±0.00059 0.935 
t 1/2, λz (min) 124±16 123±14 0.887 
MRT0-∞ (min) 210.77±22.68 205.74±22.15 0.766 
MRT0-480 (min) 150.60±22.36 147.89±19.23 0.877 
AUCbECF/AUCplasma 0.0503±0.0047 0.0489±0.0098 0.822 
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Table 3.17 Pharmacokinetic parameters (mean±SD) of PHT after i.p. 
administration of 6 mg/kg PHT with or without the concomitant i.p. 
administration of 10 mg/kg FBM in rats. 
PK parameters PHT (n=6) PHT+FBM (n=6) p-Value 
Cmax (μg/mL) 1.265±0.238 1.383±0.184 0.303 
Tmax (min) 37±8 37±8 - 
AUC0-∞ (μg*min/mL) 228.90±55.09 251.90±42.32 0.475 
AUC0-480(μg*min/mL) 199.03±41.60 212.66±33.43 0.532 
λz (min-1) 0.00512±0.00107 0.00459±0.00034 0.297 
t 1/2, λz (min) 140±24 152±12 0.986 
MRT0-∞ (min) 221.87±39.81 241.55±18.09 0.329 
MRT0-480 (min) 155.11±12.34 158.03±6.14 0.625 
CL/F (mL/min) 7.303±1.954 6.403±1.324 0.371 












3.4.2.3.2 FBM neuropharmacokinetics and pharmacokinetics 
 
The mean bECF and plasma concentration-time profiles of the FBM after i.p. 
administration of a single dose of 10 mg/kg in the presence and absence of PHT 
(6 mg/kg) are shown in Figure 3.10. The estimates of neuropharmacokinetic 
and pharmacokinetic parameters were summarized in Table 3.18 and Table 
3.19, respectively. A small but statistically significant increase (by 20%, p<0.05) 
was found for FBM AUCbECF/AUCplasma value in the combination group 
compared to the FBM alone group. Another smaller increase (by 6%, p<0.05) 
was observed for λz in plasma. The other neuropharmacokinetic and 
pharmacokinetic parameters were not affected by adding 6 mg/kg PHT.  
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FBM bECF time course (Mean ± SD)
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FBM plasma time course (Mean ± SD)
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Figure 3.10 bECF concentration-time profile (A) and plasma 
concentration-time profile (B) of FBM after i.p. administration at a dose of 10 
mg/ml in rats with (○) or without (●) a concomitant i.p. injection of 6 mg/kg 






Table 3.18 Neuropharmacokinetic parameters (mean±SD) of FBM after i.p. 
administration of 10 mg/kg FBM with or without the concomitant i.p. 
administration of 6 mg/kg PHT in rats. 
NeuroPK parameters FBM (n=6) FBM+PHT (n=6) p-Value 
Cmax (μg/mL) 0.359±0.037 0.380±0.080 0.664 
Tmax (min) 83±15 90±11 0.53 
AUC0-∞ (μg*min/mL) 90.21±12.20 96.86±13.92 0.548 
AUC0-480(μg*min/mL) 79.21±11.05 86.30±14.69 0.528 
λz (min-1) 0.00489±0.00048 0.00495±0.00054 0.676 
t 1/2, λz (min) 143±14 142±16 0.742 
MRT0-∞ (min) 250.71±17.98 247.00±24.32 0.691 
MRT0-480 (min) 189.77±4.64 191.58±7.04 0.534 
AUCbECF/AUCplasma 0.0586±0.0068 0.0707±0.0137 0.008 
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Table 3.19 Pharmacokinetic parameters (mean±SD) of FBM after i.p. 
administration of 10 mg/kg FBM with or without the concomitant i.p. 
administration of 6 mg/kg PHT in rats. 
PK parameters FBM (n=6) FBM+PHT (n=6) p-Value 
Cmax (μg/mL) 5.352±0.493 5.230±0.916 0.839 
Tmax (min) 75±25 60±0 0.272 
AUC0-∞ (μg*min/mL) 1553.42±247.10 1402.35±256.17 0.326 
AUC0-480(μg*min/mL) 1325.00±192.45 1204.16±180.85 0.364 
λz (min-1) 0.00447±0.00045 0.00474±0.00103 0.026 
t 1/2, λz (min) 156±15 153±37 0.61 
MRT0-∞ (min) 254.94±21.34 244.34±53.23 0.369 
MRT0-480 (min) 177.98±7.21 170.88±15.89 0.108 
CL/F (mL/min) 1.731±0.312 1.952±0.578 0.381 




In this study, a rat neuropharmacokinetic and pharmacokinetic model was 
established using microdialysis and jugular vein cannulation techniques. By 
these in vivo techniques it is possible to monitor the drug and metabolite 
concentrations in blood and tissue of animals simultaneously for metabolic and 
pharmacokinetic purpose (58). As there is no net fluid exchange, continuous 
sampling for long periods of time without disturbing the pharmacokinetics is 
 84 
possible. Furthermore, it has been shown in several studies that the BBB 
remains intact shortly after insertion of the microdialysis probe (59). 
Microdialysis has several advantages over classical methods in examining the 
distribution into the CNS of drugs. Uncertainty as to the blood content of brain 
tissue homogenate can produce large errors in brain drug concentration (60). 
The increases in bECF levels of AEDs by P-gp or MRP inhibition in rats are 
relatively small, so such increases may be missed when the concentrations of 
these AEDs in whole brain tissue are chosen as the neuropharmacokinetic data 
(61). In contrast, microdialysis allows sampling without any vascular 
contamination, provided that the BBB is intact after probe insertion. As 
described in Chapter 1, unlike other methods such as quantitative 
autoradiography and brain homogenate method, microdialysis can differentiate 
between bound and free drug concentrations. Drug concentrations in 
microdialysis dialysate only reflect unbound drug concentrations in bECF.  
 
Although a sensitive LC-MS method was established to determine PHT and 
HPPH simultaneously, HPPH was not detected in brain dialysate at low dose 
level. This indicates that there is very little HPPH in rat brain. It is believed that 
it would be difficult for HPPH to pass BBB because the metabolite HPPH is 
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more hydrophilic compared to the parent drug PHT.   
 
At first, a long wash-out period of three weeks was used for the animal study at 
high dose level. Then a shorter wash-out period of one week was used for low 
dose level. Results of statistical analysis showed that both long and short 
wash-out period did not affect the NeuroPK and PK parameters. So a wash-out 
period of one week was adopted for the subsequent animal studies. 
  
Neuropharmacokinetic and conventional pharmacokinetic studies described in 
the present chapter demonstrate that PHT and FBM increased each other’s brain 
bioavailability at the dose of 50 mg/ml (for both). However, such effect was not 
observed at a much lower dose of 6 mg/ml (for PHT) and 10 mg/kg (for FBM). 
The underlying mechanisms were unclear but the significant increases in brain 
is likely to be caused by a competitive inhibition of the brain drug transporter 
and/or the interference of the brain metabolic enzyme function. A considerable 
increase (by 56%) was observed for PHT Cmax in bECF. Although this increase 
was not statistically significant (0.05<p<0.1), it could be that the distribution of 
PHT from blood into brain was enhanced to some extent. This enhanced 
distribution could account largely for the significant increase of PHT AUC in 
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bECF because the t1/2, λz in bECF, the disposition kinetic parameter, was not 
changed much. The unchanged t1/2, λz indicates that the elimination in brain 
might be not affected much in the presence of FBM. Although not all the 
inhibitors of a certain drug transporter are also the substrates of this transporter, 
compounds that are substrates are usually also inhibitors because the substrates 
of this transporter may share a specific binding site for which they can compete. 
Then concentration and affinity of the simultaneously present competitor will 
ultimately determine which compound will act as an inhibitor in a given drug 
combination and lead to an accumulation of the competitor (48). A number of 
studies have been carried out in the past by many research groups (14; 46; 55; 
62). However, regarding the direct interactions of PHT and FBM with the 
transporters, disagreements in the literature data prevent the effectiveness of 
drawing any final conclusion. Nevertheless, considerable evidence has been 
found for the modulation on drug transporter activities by the AEDs. As 
summarized in the introduction, uptake of PHT into rat brains was enhanced by 
the administration of P-gp inhibitors, cyanide, verapamil or PSC833 (45) as 
well as the MRP2 inhibitor probenecid (46; 62). Local perfusion of verapamil 
via the microdialysis probe to cortex of rats’ brain increased the concentration 
of felbamate in the extracellular fluid of the cerebral cortex in a significant 
manner (55). So it is likely that FBM may inhibit some PHT transporters’ 
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function on BBB which further lead to an accumulation of PHT in brain. 
However, types of transporters involved and the extent of the inhibition remain 
to be determined. This can also explain why there is no change in brain 
bioavailability of PHT at a lower dose of FBM because the blood concentrations 
of FBM are not high enough to show inhibitory effects at a lower dose level. 
Similarly, PHT may play the same role as FBM in the inhibition of drug 
transporters on BBB. But the extent of the inhibition may be not as large as 
FBM because the coadministration of PHT only caused a small (by 28%) and 
not significant (0.05<p<0.1) change of FBM Cmax in bECF. At the same time, a 
considerable increase (by 72%) of FBM t1/2, λz in bECF might indicate that the 
elimination of FBM in brain could be reduced in the presence of PHT although 
the increase of t1/2, λz was not statistically significant. This reduced elimination 
of FBM might be caused by the decreased metabolism in brain in the presence 
of PHT.   
 
What is also interesting is that the co-administration of PHT and FBM did not 
significantly influence their plasma PK profiles, irrespective of the dose used. 
Pharmacokinetic interactions have been reported between FBM and PHT after 
chronic administration. In a clinical trial conducted in 10 epileptic patients, 
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co-administration of FBM with PHT for 2 weeks significantly increased PHT 
bioavailability (63). PHT Cmax was increased from 15.9 µg/ml at baseline to 
20.9 µg/ml after 1,200 mg/day FBM and to 26.8 µg/ml after 1,800 mg/day FBM. 
Interestingly, FBM Cmax and AUC values were reduced, and apparent plasma 
clearance was increased compared to data obtained from FBM monotherapy. In 
vitro studies show that FBM is the substrate of CYP3A4. So PHT which is a 
CYP3A4 inducer increases FBM plasma clearance. At the same time, FBM has 
been demonstrated to be an inhibitor of CYP2C19 in vitro which accounts for 
the reduced plasma clearance of PHT(50). Interactions involving the induction 
of CYP isoenzymes are apparently a slow process than those resulting from 
inhibition because induction of a CYP isoenzyme requires the expression of 
new protein and this may need several days or weeks of drug administration 
before any noticeable effect can be seen. In contrast to the findings of the 
pharmacokinetic interactions beween PHT and FBM after chronic 
co-administraion in humans, the present findings in rats indicate that acute 
exposure to the co-administration of the AEDs results in changes in their 
neuroPK but not PK profiles. This further suggests that brain disposition is 
more sensitive to such co-administration of the drugs than other tissue 
disposition. As hepatic CYP2C is one of the most metabolic enzymes for PHT 
and CYP3A4 contributes a lot to the metabolism of FBM, drug transporters 
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located in liver, such as P-gp and MRP, should also contribute to its 
conventional PK profile. Based on our results, it could be that the factors (such 
as transporters and metabolic enzymes) that accounted for the enhanced brain 
drug bioavailability did not yield a comparable effect on other tissues. Such 
assumption was supported by the following evidence in literature. Transporter 
proteins located in BBB, such as P-gp, has shown more resistance than other 
locations to some drugs. A 20-fold difference was found on the brain 
concentrations of digoxin between mdr1a/1b (-/-) mice and wild type mice after 
oral administration (64). However, only 1.9-fold difference in digoxin 
concentration was found in the plasma. As digoxin is a P-gp substrate that 
undergoes comparatively low metabolism (64), the results indicate higher 
functional activity of P-gp in the brain than the combined activity in other 
tissues, such as liver and kidney.  
 
It is also possible that opposite effects that exist in other tissues diminished the 
modulation as seen in the brain. In other words, AEDs investigated in our study 
interplay with more than one type of drug transporters or metabolic enzymes. 
As the consequence of such interplay, plasma drug concentrations remained 
unchanged albeit influenced brain drug level. Nevertheless, in consideration of 
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the complicity of the in vivo system as well as the metabolic pathways of the 
drug, it is very hard to predict the interactions between AEDs and transporters 
and/or enzymes. The underlying mechanisms remain to be verified using other 






















CHAPTER 4  
 
NEUROPHARMACOKINETIC INTERACTION BETWEEN 











In addition to PHT and FBM, carbamazepine (CBZ) is also among the most 
commonly prescribed antiepileptic drugs and is often used to treat childhood 
epilepsy. Apart from being used in the treatment of simple or complex partial 
seizures and generalized tonic-clonic seizures (65; 66), it is also used in the 
treatment of trigeminal neuralgia and psychiatric disorders, particularly bipolar 
depression. The combination use of PHT/CBZ may lead to drug-drug 
interactions and the evidence exists in the following aspects. 
 
First of all, several clinical studies have investigated the pharmacokinetic 
interactions between PHT and CBZ (67-75) .A clinical study conducted on 
epileptic children has shown that patients receiving the combination therapy of 
CBZ and PHT tended to have lower total CBZ levels than those patients 
receiving CBZ alone. In vitro studies have shown that both CBZ and PHT are 
potent enzyme inducers and can increase the levels of both CYP and UGT 
isoenzymes. CYP3A4 is the main enzyme system responsible for the 
transformation of CBZ to carbamazepine-10,11-epoxide (CBZ-E) which is the 
most important metabolite of CBZ. In this regard, the decrease in CBZ serum 
levels after the combination use with PHT may be attributed to the induction of 
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CYP3A4 by PHT.  
 
So far the effect of CBZ on the pharmacokinetics of PHT is still controversial 
and inconsistent results have been reported by different research groups (76). 
Some clinical studies have shown that CBZ can reduce both PHT plasma 
concentrations at steady-state and elimination half-life of PHT (76). These 
effects can be explained by the induction of CYP2C enzymes by CBZ. But 
other clinical studies also reported a higher PHT plasma concentrations and a 
longer elimination half-life after the combination use with CBZ (76). These 
inconsistent data suggest that CBZ may also inhibit other metabolic enzymes 
and more studies are necessary for clarifying any controversy.  
 
Another important characteristic of CBZ is “autoinduction” that CBZ can 
induce its own metabolism after a long term administration. This is because 
CBZ is not only the substrates of CYP1A2 and CYP3A4 but also the inducers 
of these two CYP450 isoenzymes. 
 
CBZ, in one report, was suggested to be a non-P-gp substrate but CYP3A4 
substrate (77). In this study, there systems were employed to investigate the 
possible interaction between CBZ and P-gp: mdr1a/1b (-/-) and wild-type mice 
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as an in vivo model; Caco-2 cells with a high P-gp expression and flow 
cytometry in lymphocytes using rhodamine 123, a fluorescent substrate for P-gp 
as in vitro models. Both in vivo and in vitro studies showed that CBZ was not a 
P-gp substrate. Another in vitro study conducted on bovine retinal endothelial 
cells also showed CBZ was not affected by P-gp (78). However, another in vivo 
study using microdialysis on rats demonstrated that both P-gp and MRP 
participate in the regulation of extracellular brain concentrations of CBZ. 
Enhanced CBZ in the extracellular fluid of the cerebral cortex was achieved by 
local perfusion with verapamil or probenecid via the microdialysis probe (79). 
And the author of this study also suggested in another review (80) that the value 
of knockout mice in drug transporter study was limited especially when such 
models were used to investigate the distribution of AEDs into brain because of 
the following two reasons: (1) another transport protein may take over the 
function of one that has been knocked out; (2) considering the relatively small 
increases in extracellular brain levels of AEDs by P-gp or MRP inhibition in rats, 
such increases may be missed when these AEDs are determined in whole brain 
tissue, as was done in the studies using knockout mice. The study using bovine 
retinal endothelial cells also showed that CBZ were not P-gp inhibitors but PHT 
inhibited P-gp. However another in vitro study conducted on L-MDR1 cells (a 
cell line generated by transfection of the porcine kidney epithelial cell line 
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LLC-PK1 with the human MDR1gene), the parental cell line LLC-PK1 and 
porcine brain capillary endothelial cells showed that CBZ has a stronger 
inhibitory effect on P-gp compared with several other AEDs: phenytoin, 
lamotrigine and valproate (48).  
 
Cumulative in vitro and in vivo data suggest that chronic exposure to PHT or 
CBZ may affect drug transporter expression and activity Full understanding of 
interactions between PHT/CBZ and the transporters remains to be established as 
yet. In a study carried out on 7 healthy volunteers, CBZ induced intestinal 
MDR1 mRNA, MRP2 mRNA, and MRP2 protein but not the P-gp protein 
content (81). Such effects may be fully or partially contributed by activation of 
the nuclear pregnane X receptor in that the drug is known to be an inducer of 
cytochrome P450 (CYP) 3A4 after binding to the nuclear pregnane X receptor 
(82). It is also shown that after carbamazepine, metabolic clearance of 
intravenous talinolol was significantly increased. Oral absorption of talinolol 
was significantly lower after CBZ comedication. As talinolol is considered as 
one of the nonmetabolic P-gp substrate, the result indicates CBZ interacts with 
P-gp substrate drugs due to the modulation on the transporter expression. 
Unfortunately, besides data on human intestine, the author failed to provide 
similar data on human brain tissue which may be more meaningful for AEDs. 
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In another study using culture rat astrocytes, phenytoin and carbamazepine 
induced the overexpression of Pgp in astrocytes in a dose- and time-dependent 
manner (47) as reviewed in the previous chapter. However, the dose for CBZ 
that exhibits significant effect was beyond the therapeutic plasma 
concentrations.  
 
Similar to the last chapter, the objective of this investigation is to investigate 
pharmacokinetic and neuropharmacokinetic interactions between PHT and CBZ 




4.2.1 Chemicals and Reagents 
 
Carbamazepine (CBZ) and its main metabolite carbamazepine-epoxide 
(CBZ-E); 5,5-Diphenyl-2,4-imidazolidinedione (phenytoin, PHT) and its main 
metabolite 5-(4-Hydroxyphenyl)-5-phenylhydantoin (HPPH) were obtained 
from Sigma-Aldrich (Singapore). Acetonitrile and methanol (HPLC grade) was 
purchased from Mallinckrodt Baker, Inc (Paris, Kentucky). Phosphoric acid and 
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hydrochloride (37%), all of analytical reagent grade, were obtained from 
Lab-Scan Analytical Science (Dublin, Ireland). Ketamine was from obtained 
from Laboratory Animal Centre, National University of Singapore. Heparin was 




The HPLC and microdialysis systems employed were the same as described 




4.3.1 HPLC and LC-MS/MS assay validation 
 
4.3.1.1 HPLC assay for carbamazepine in rat plasma and bECF 
 
The high performance liquid chromatography with UV detector was used for 
the determination of CBZ in plasma at high dose level and low dose level as 
well as PHT in bECF at high dose level. This method was a modification of the 
method of Mandrioli et al (83). The mobile phase for the separation of CBZ 
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consisted of methanol –20mM pH 6.8 phosphate buffer (50:50). Sample 
injection loop was 20 μl. The mobile phase was filtered with a 0.20 μm filter 
membrane (Nylon, 47mm, phenomenex, USA) prior to its use. The pump was 
set at a flow rate of 0.8 ml/min. The peak was detected at the wavelength of 212 
nm.  
 
4.3.1.1.1 Standard stock solution, calibration and quality control samples 
 
Stock solution of CBZ was prepared by dissolving weighed amount of CBZ in 
acetonitrile to obtain a concentration of 1000 µg/ml. Working solution was 
prepared by mixing the stock solution with acetonitrile or aCSF to final 
concentrations. The calibration standards were freshly prepared everyday by 
diluting the stock solutions with plasma or aCSF to the following concentrations: 
0.031, 0.062, 0.155, 0.388, 0.776, 1.94 and 3.880µg/ml for rat plasma samples; 
0.006, 0.031, 0.062, 0. 124, 0.248, 0.496 and 0.992 µg/ml for aCSF samples. 
For the quality control (QC) samples, the following concentrations were chosen: 
0.031, 0.388 and 3.880 µg/ml for plasma samples as well as 0.006, 0.062 and 
0.496 µg/ml for aCSF samples. All the stock solutions and QC samples are 
protected from light and stored at –20 °C. 
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4.3.1.1.2 Plasma sample processing and assay validation 
 
Rat plasma samples were processed following the same protocol as for PHT. 
The assay was validated using the calibration standards and QC standards 
following the same protocol as for PHT. 
 
4.3.1.2 LC-MS/MS assay for CBZ and CBZ-E in bECF 
 
This LC-MS/MS method was used for the determination of CBZ in bECF at 
low dose level. 
 
4.3.1.2.1 Mass spectrometry and HPLC conditions 
 
The LC-MS/MS system consisted of an Agilent 1100 series liquid 
chromatograph (including an Agilent 1100 LC Binary Pump and an Agilent 
1100 G1367A autosampler) coupled to an Applied Biosystems QTrap mass 
spectrometer equipped with a Turbo IonSpray interface. The positive ion mode 
was performed. The MS/MS conditions were tuned by the continuing infusion 
of drug to the mass system and set as follows. (1) The multiple reaction monitor 
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(MRM) mode was set at 237.80→194.90 m/z for CBZ; 253.00→180.00 m/z for 
CBZ-E. (2) Nebulizer gas (Gas 1) was set as 60; auxiliary gas (Gas2) was set as 
50; temperature of the turbo gas was set as 400 ºC; interface heater was set off; 
curtain gas was set as 10; ion spray voltage was 3000 V; CAD was set as low. (3) 
Other settings included declustering potential: 100 V for CBZ and 110 V for 
CBZ-E; entrance potential: 10 V for CBZ and 11V for CBZ-E; cell entrance 
potential: 22.67 V for CBZ and 23.17 for CBZ-E; cell exit potential: 3.0 V for 
CBZ and 3.5 for CBZ-E; and collision energy: 26 eV for CBZ and 40eV for 
CBZ-E.  Peak integration was finished by the software version: Analyst 1.4.1. 
A reversed-phase C18 column (5 μm, 150 mm×2.0 mm i.d.) was used. The 
mobile phase consisted of acetonitrile–10 mM ammonium acetate buffer (50:50, 
v/v) at the flow rate of 0.2 ml/min.  
 
4.3.1.2.2 Standard stock solution, calibration and quality control samples 
 
Stock solutions of CBZ and CBZ-E were prepared separately by dissolving 
weighed amount of CBZ and CBZ-E in MeOH to obtain a concentration of 100 
µg/ml. Working solutions were prepared by mixing the respective stock 
solutions with aCSF to final concentrations. For the standard curve, the final 
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concentrations of CBZ and CBZ-E in aCSF used were as follows: 212, 106, 
42.4, 21.2, 10.6, 5.3 and 1.06ng/ml for CBZ and 100, 50, 20, 10, 5, 2.5, and 
0.5ng/ml for CBZ-E. The calibration standards were freshly prepared on each 
analysis day by diluting the working solutions with aCSF to appropriate 
concentrations. For the quality control (QC) samples, the concentrations of 
standards in medium were 212, 21.2 and 1.06 ng/ml for CBZ and 100, 10 and 
0.5 ng/ml for CBZ-E. All the stock solutions and QC samples were protected 
from light and stored at –20 °C. 
 
4.3.1.2.3  Assay validation 
 
The linearity, within-day and between day accuracy, and absolute recovery were 
determined using the calibration standards and QC standards following the 
same protocols as described in the HPLC methods.  
 





Male Sprague Dawley rats were obtained from the same source as described in 
Chapter 3. 
 
4.3.2.2 Drug administration 
 
The three-period, three- sequence crossover experimental design was employed 
for each of low and high doses in the study.  The rats in each group received 
PHT alone, CBZ alone or the compbined PHT and CBZ on different occasions 
with a wash-out period of a week between the treatments as shown in Table 4.1. 
The body weight of the rat was recorded prior to each drug administration. 
 
Table 4.1 PHT and CBZ administration scheme to rats 
 1# (Day 1) 2# (Day8) 3# (Day 15) 
Rat 1  CBZ PHT+CBZ PHT 
Rat 2 CBZ PHT+CBZ PHT 
Rat 3 PHT+CBZ PHT CBZ 
Rat 4 PHT+CBZ PHT CBZ 
Rat 5 PHT CBZ PHT+CBZ 




4.3.2.3 Microdialysis experiments 
 
4.3.2.3.1 In vitro recovery of microdialysis probe for PHT and CBZ  
 
CBZ and PHT were dissolved in aCSF in a micro-Eppendorf tube, with the 
concentrations of 0.5 μg/ml and 2.0 μg/ml, respectively, and a final volume of 
1.5 ml was achieved. The microdialysis probe was immersed into aCSF and 
perfusion of the CBZ and PHT mixture was started by a CMA/100 
microinjection pump with the flow rate of 2 μl/min. The dialysate sample was 
subsequently collected by a CMA/170 refrigerated fraction collector every 20 
minutes. A total of 4 dialysate samples were collected and directly subject to the 
HPLC assay. Another two parallel experiments were performed with the 
respective concentration of 0.05 μg/ml for CBZ and 0. 1 μg/ml for PHT; and 
0.01 μg/ml for CBZ and 0. 01 μg/ml for PHT. 
 
4.3.2.3.2 Microdialysis and jugular vein canulation surgery procedure 
 
Microdialysis and jugular vein canulation surgery procedure was the same source 
as described in Chapter 3. 
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4.3.2.3.3 bECF and blood sampling 
 
The same bECF and blood sampling techniques were employed as described in 
Chapter 3. 
 
4.3.3 Data Analysis 
 
4.3.3.1 Neuropharmacokinetic and pharmacokinetic analysis 
 
The same data analyses were employed as described in Chapter 3. 
 
4.3.3.2 Statistical analysis 
 





4.4.1 HPLC and LC-MS/MS assay validation for CBZ 
 
   4.4.1.1 HPLC assay for CBZ in plasma and bECF 
 
Plasma CBZ was assayed using a RP-HPLC method. The chromatogram of 
CBZ was shown in Figure 4.2.  
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Figure 4.1 Chromatograms of rat plasma and bECF sample. A, blank plasma 
sample; B, plasma containing  0.56 μg/ml CBZ; C, blank rat bECF sample; D, 
rat bEFC sample containing 0.031 μg/ml CBZ. 
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This assay method was robust, with as low intra-day and inter-day variations as 
≤10% for CBZ plasma samples in the concentration range of 0.043-2.752 µg/ml 
and for CBZ bECF samples in the concentration range of 0.006-0.992 µg/ml 
(Table 4.3). The assay also showed a good absolute recovery for plasma 
samples as shown in Table 4.4. The peak area showed a good linear relationship 
for both plasma samples and bECF samples and the linear regression equations 
were calculated as y = 47236x + 2563 (r2=0.9996) for plasma samples and 
y=92358x-1254 for bECF samples (r2=0.9993). LOQ were 0.043 µg/ml and 











Table 4.2 Intra-day and inter-day variations in peak area for CBZ plasma and 
bECF samples in the concentration range of 0.043 and 2.752 µg/ml. Data are 










2.752 2.541  2.88 92.35±2.66 
0.344 0.332  8.56 96.44±8.26 
Intra-day 
plasma 
0.043 0.042  6.32 97.25±6.15 
2.752 2.651  7.69 96.32±7.41 
0.344 0.317  4.39 92.04±4.04 
Inter-day 
plasma 
0.043 0.046  2.08 106.34±2.21 
0.006 0.005  6.83 86.21±5.89 
0.062 0.057  4.91 92.25±4.53 
Intra-day 
bECF 
0.496 0.456  3.71 91.87±3.41 
0.006 0.005  7.92 91.14±7.22 
0.062 0.060  4.35 96.66±4.20 
Inter-day 
bECF 






Table 4.3 Absolute recovery for CBZ plasma and bECF samples as detected by 




Recovery (%) R.S.D.(%) 
2.752 98.98 8.95 
0.344 99.23 6.32 Plasma 
0.043 96.32 4.36 
0.006 96.35 7.56 
0.062 95.32 3.21 bECF 
0.496 99.76 6.88 
 
4.4.1.2 LC-MS method for CBZ and CBZ-E in bECF 
 
To explore the LC-MS analysis method for CBZ and its metabolite CBZ-E, MS 
detection methods were firstly established. The respective MS spectrums of 
these two compounds were shown in Figure 4.3 and 4.4, respectively. 
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 +MS2 (237.30) CE (26): 91 MCA scans from Sample 1 (CBZ MS 2) of CBZ.wiff (Turbo Spray) Max. 1.4e6 cps.



























Figure 4.2 MS/MS spectra and transitions for CBZ  
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 +MS2 (253.30) CE (26): 301 MCA scans from Sample 2 (CBZ-E MS2-2) of CBZ-E.wiff (Turbo Spray) Max. 4.8e5 cps.







































Figure 4.3 MS/MS Spectra and transitions for CBZ-E  
The LC-MS/MS analysis method for CBZ and CBZ-E was subsequently 
validated using aCSF samples. The chromatogram was shown in Figure 4.6. 
Linear regression equations for CBZ and CBZ-E were CBZ: y=1180x+4690 
(r2=0.9972) and CBZ-E: y=7620x+1260 (r2=0.9997), respectively. The assay 
provided a rapid and accurate method to detect these two compounds and the 
intra- and inter-day variations were summarized in Table 4.4. The absolute 
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recovery was also calculated and listed in Table 4.5. LOQ were 1.06 ng/ml and 





Figure 4.4 LC-MS/MS chromatogram of CBZ (1.06 ng/ml) and CBZ-E (0.5 
ng/ml) obtained in aCSF solution. A, blank aCSF sample; B, aCSF sample 
containing 1.06 ng/ml CBZ and 0.5 ng/ml CBZ-E. 
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Table 4.4 Intra-day and inter-day variation in peak area for aCSF samples of 











212 216.88 3.5 102.3±3.58 
21.2 20.27 6.2 95.6±5.93 
Intra-day 
CBZ 
1.06 0.96 7.1 90.1±6.40 
212 195.68 4.8 92.3±4.43 
21.2 20.90 7.8 98.6±7.69 
Inter-day 
CBZ 
1.06 0.98 9.5 92.8±8.82 
100 95.60 4.8 95.6±4.59 
10 9.10 6.2 91±5.64 
Intra-day 
CBZ-E 
0.5 0.53 7.1 105.5±7.49 
100 97.80 4.8 97.8±4.69 
10 9.55 6.2 95.5±5.92 
Inter-day 
CBZ-E 







Table 4.5 Absolute recovery for bEFC samples of CBZ and CBZ-E as detected 




Recovery (%) R.S.D.(%) 
212 98.7 3.6 
21.2 92.8 8.6 CBZ 
1.06 106.8 3.5 
100 99.9 5.6 
10 98.6 4.5 CBZ-E 
0.5 105.3 7.9 
 
 
4.4.2 Animal study 
 
   4.4.2.1 Rat body weight and microdialysis probe in vitro recovery 
 
The rat body weight for both the high and low dose investigations (Tables 4.6 
and 4.7) was monitored throughout the microdialysis experiments. The body 
weight was increased gradually and no significant drop in the body weight was 




Results of statistical analysis also showed that neuropharmacokinetic and 
pharmacokinetic parameters were not affected by different administration 
periods and regimen sequences. 
 
Table 4.6 The body weight of rats undergone microdialysis. Rats were 
administered with 10 mg/kg of CBZ, 50 mg/kg of PHT or both combination 
were labeled as CBZ, PHT or CBZ+PHT. 
 1# (Day 1) 2# (Day8) 3# (Day 15) 
Rat 1 238g (CBZ) 262g (PHT+CBZ) 278g (PHT) 
Rat 2 245g (CBZ) 266g (PHT+CBZ) 282g (PHT) 
Rat 3 234g (PHT+CBZ) 258g (PHT) 281g (CBZ) 
Rat 4 243g (PHT+CBZ) 271g (PHT) 293g (CBZ) 
Rat 5 229g (PHT) 267g (CBZ) 285g(PHT+CBZ) 
Rat 6 231g (PHT) 257g (CBZ) 289g (PHT+CBZ) 
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Table 4.7 The body weight of rats undergone microdialysis. Rats were 
administered with either 2 mg/kg of CBZ, 6 mg/kg of PHT or both combination 
were labeled as CBZ, PHT or CBZ+PHT. 
 1# (Day 1) 2# (Day8) 3# (Day 15) 
Rat 1 236g (CBZ) 263g (PHT+CBZ) 293g (PHT) 
Rat 2 230g (CBZ) 258g (PHT+CBZ) 288g (PHT) 
Rat 3 242g (PHT+CBZ) 271g (PHT) 297g (CBZ) 
Rat 4 240g (PHT+CBZ) 267g (PHT) 293g (CBZ) 
Rat 5 236g (PHT) 255g (CBZ) 282g(PHT+CBZ) 
Rat 6 241g (PHT) 264g (CBZ) 287g (PHT+CBZ) 
 
Microdialysis probe in vitro recovery data showed a good consistence with the 
range of drug concentration tested. The mean±SD in vitro relative recovery of 
PHT for the 6 microdialysis probes was 18.5±1.5% (2 μg/mL), 20.0±1.8% (0.1 
μg/mL) and 22.3±2.1% (0.01 μg/mL); that of CBZ was 22.3±1.7% (0.5 μg/mL), 
24.4±1.5% (0.05 μg/mL) and 27.5±1.6% (0.01 μg/mL). These recovery values 
were then used to calculate in vivo concentration data. An average of these 
recovery values at different concentrations for each drug was then used to 
calculate in vivo concentration data. The following equation was used to 
calculate drug concentrations in bECF: CbECF = Cdial / Rav, where CbECF is the 
drug concentrations in bECF, Cdial is the measured drug concentrations in 
dialysate and Rav is the in vitro recovery value of microdialysis probe. 
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4.4.2.2 Neuropharmacokinetic and pharmacokinetic interaction between 
PHT and CBZ at a high dose 
 
4.4.2.2.1 PHT neuropharmacokinetics and pharmacokinetics 
 
The mean bECF and plasma concentration-time profiles of the PHT after i.p. 
administration of a single dose of 50 mg/kg in the presence and absence of CBZ 
(10 mg/kg) are shown in Figure 4.5. The estimates of neuropharmacokinetic 
and pharmacokinetic parameters were summarized in Table 4.8 and Table 4.9, 
respectively. Neuropharmacokinetic and pharmacokinetic interactions between 
PHT and CBZ were investigated by analysis of the drug concentrations in rat 
bECF and plasma, respectively, after a single i.p. dose of 50 mg for both drugs. 
Figure 4.5 illustrates the PHT plasma and bECF concentration-time profiles in 
the absence or presence of a concomitant i.p. injection of CBZ. 
Co-administration of CBZ significantly increased dialysate level of PHT as 
reflected by the shifting-up of the drug bECF-concentration profile (Figure 4.5 
A). Such modulation was assessed by examining the neuroPK parameters of 
PHT as listed in Table 4.8. A significant increase (by 71%, p<0.05) was found 
in the PHT Cmax level in bECF with the coadministration of CBZ. The PHT 
AUC0-∞ and AUC0-480 values in bECF were significantly increased (by 140% 
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and 94%, respectively; p<0.05 and p<0.05). A significant increase was also 
observed for AUCbECF/AUCplasma (by 50%, p<0.05). However, the other 
parameters such as Tmax and t1/2, λz of PHT, were not affected by the 
coadministration of CBZ. In contrast, coadministration of CBZ did not result in 
a significant change of PHT in most of the plasma PK parameters (Table 4.9) 
except λz , t 1/2, λz and MRT values. Neither was there any statistically significant 
change found in the PHT concentrations at various time-points between PHT 
alone group and the combination (PHT + CBZ) group (Figure 4.5 B). 
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PHT bECF time course (Mean ± SD)
Time (min)

























PHT plasma time course (Mean ± SD)
Time (min)


























Figure 4.5 bECF concentration-time profile (A) and plasma concentration-time 
profile (B) of PHT after i.p. administration at a dose of 50 mg/kg in rats with (○) 
or without (●) a concomitant i.p. injection of 10 mg/kg CBZ. Data were 






Table 4.8 Neuropharmacokinetic parameters (mean±SD) of PHT after i.p. 
administration of 50 mg/kg PHT with or with out the concomitant i.p. 
administration of 10 mg/kg CBZ in rats. 
NeuroPK parameters PHT (n=6) PHT+CBZ (n=6) p-Value 
Cmax (μg/mL) 0.684±0.129 1.171±0.266 0.012 
Tmax (min) 107±16 120±28 0.200 
AUC0-∞ (μg*min/mL) 260.52±75.55 614.02±273.16 0.049 
AUC0-480(μg*min/mL) 193.20±45.88 374.9999.82 0.011 
λz (min-1) 0.00335±0.00063 0.00295±0.00140 0.579 
t 1/2, λz (min) 214±42 285±132 0.313 
MRT0-∞ (min) 355.55±60.90 474.90±172.19 0.196 
MRT0-480 (min) 213.53±13.24 226.47±8.66 0.120 
AUCbECF/AUCplasma 0.0438±0.0224 0.0656±0.0278 0.017 
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Table 4.9 Pharmacokinetic parameters (mean±SD) of PHT after i.p. 
administration of 50 mg/kg PHT with or with out the concomitant i.p. 
administration of 10 mg/kg CBZ in rats. 
PK paraeters PHT (n=6) PHT+CBZ (n=6) p-Value 
Cmax (μg/mL) 21.038±4.154 19.592±3.519 0.616 
Tmax (min) 30±11 52±24 0.216 
AUC0-∞ (μg*min/mL) 6753.32±2870.48 9468.91±1793.57 0.110 
AUC0-480(μg*min/mL) 5089.46±1501.20 5826.48±1118.33 0.417 
λz (min-1) 0.00336±0.00070 0.00229±0.00018 0.007 
t 1/2, λz (min) 217±59 303.77±24.44 0.018 
MRT0-∞ (min) 324.30±80.59 482.23±41.46 0.013 
MRT0-480 (min) 185.87±12.68 208.89±6.65 0.004 
CL/F (mL/min) 2.106±0.533 1.422±0.233 0.069 
Vz/F (mL) 623.39±62.04 625.06±129.27 0.986 
 
 
4.4.2.2.2 CBZ neuropharmacokinetics and pharmacokinetics 
 
The mean bECF and plasma concentration-time profiles of the CBZ after i.p. 
administration of a single dose of 50 mg/kg in the presence and absence of PHT 
(50 mg/kg) are shown in Figure 4.6. The estimates of neuropharmacokinetic 
and pharmacokinetic parameters were summarized in Table 4.10 and Table 4.11, 
respectively. 
 
In addition to the neuroPK and PK profiles of PHT in combination with CBZ, 
the potential impacts of PHT on CBZ neuroPK and PK profiles were also 
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evaluated. Similar to what was observed in PHT profiles, coadministration of 
PHT given as a single dose of 50 mg/ml also led to a shifting of CBZ bECF 
level to higher concentrations as compared to those seen in the CBZ alone 
group (Figure 4.6 A). Such an increase in bECF CBZ level was assessed by the 
change in neuroPK parameters of CBZ as summarized in Table 4.10. A 
significant increase in AUC0-∞ and AUC0-480 (by 67% and 85%, respectively; 
p<0.05 and p<0.05) as well as Cmax (by 64%, p<0.05) were found.. On the other 
hand, such combination of single-dose PHT and CBZ did not yield any altered 
plasma PK profile of CBZ. The calculated PK parameters of CBZ with or 
without PHT were summarized in Table 4.11. No significant changes in PK 
parameters were found between the CBZ alone group and the combination 
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CBZ plasma time course (Mean ± SD)
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Figure 4.6 bECF concentration-time profile (A) and plasma concentration-time 
profile (B) of CBZ after i.p. administration at a dose of 10 mg/kg in rats with (○) 
or without (●) a concomitant i.p. injection of 50 mg/kg PHT. Data were 






Table 4.10 Neuropharmacokinetic parameters (mean±SD) of CBZ after i.p. 
administration of 10 mg/kg CBZ with or without the concomitant i.p. 
administration of 50 mg/kg PHT in rats. 
NeuroPK parameters CBZ (n=6) CBZ+PHT (n=6) p-Value 
Cmax (μg/mL) 0.0882±.0296 0.145±0.049 0.013 
Tmax (min) 113±41 117±29 0.928 
AUC0-∞ (μg*min/mL) 40.96±23.50 68.32±28.36 0.027 
AUC0-480(μg*min/mL) 24.75±10.49 45.79±17.85 0.02 
λz (min-1) 0.00266±.0.00069 0.00275±0.00080 0.848 
t 1/2, λz (min) 280±94 271±77 0.839 
MRT0-∞ (min) 459.24±140.78 435.74±102.78 0.689 
MRT0-480 (min) 222.73±26.10 224.40±5.70 0.899 








Table 4.11 Pharmacokinetic parameters (mean±SD) of CBZ after i.p. 
administration of 10 mg/kg CBZ with or without the concomitant i.p. 
administration of 50 mg/kg PHT in rats. 
PK parameters CBZ (n=6) CBZ+PHT (n=6) p-Value 
Cmax (μg/mL) 2.611±0.503 2.570±0.664 0.93 
Tmax (min) 102±98 85±23 0.713 
AUC0-∞ (μg*min/mL) 949.14±298.03 1201.84±291.47 0.300 
AUC0-480(μg*min/mL) 703.04±154.07 783.79±174.96 0.514 
λz (min-1) 0.00402±0.00226 0.00258±0.00083 0.282 
t 1/2, λz (min) 210±86 293±92 0.187 
MRT0-∞ (min) 346.15±137.61 454.65±136.17 0.278 
MRT0-480 (min) 200.60±34.86 210.77±16.44 0.640 
CL/F (mL/min) 3.015±0.998 2.280±0.470 0.292 
Vz/F (mL) 848.27±368.06 952.36±341.16 0.633 
 
4.4.2.3 Neuropharmacokinetic and pharmacokinetic interactions between 
PHT and CBZ at a low dose 
 
4.4.2.3.1 PHT neuropharmacokinetics and pharmacokinetics 
 
The mean bECF and plasma concentration-time profiles of the PHT after i.p. 
administration of a single dose of 6 mg/kg in the presence and absence of CBZ 
(2 mg/kg) are shown in Figure 4.7. The estimates of neuropharmacokinetic and 




4.4.2.3.2 CBZ neuropharmacokinetics and pharmacokinetics 
 
The mean bECF and plasma concentration-time profiles of the CBZ after i.p. 
administration of a single dose of 2 mg/kg in the presence and absence of PHT 
(6 mg/kg) are shown in Figure 4.8. The estimates of neuropharmacokinetic and 
pharmacokinetic parameters were summarized in Table 4.14 and Table 4.15, 
respectively. 
 
In a parallel experiment, the neuroPK and PK interactions between PHT and 
CBZ were investigated with the i.p. dose of 6 mg/kg and 2 mg/kg for PHT and 
CBZ, respectively. Under such a combined low-dose regimen, CBZ failed to 
alter the bECF and plasma concentration-time profiles of PHT (Figure 4.7). Nor 
did PHT alter CBZ concentrations in bECF and plasma (Figure 4.8) as well. 
The neuroPK and PK parameters for PHT and CBZ were calculated and 
summarized in Table 4.12-15. No significant changes in the corresponding 




PHT bECF time course (Mean ± SD)
Time (min)
























PHT plasma time course (Mean ± SD)
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Figure 4.7 bECF concentration-time profile (A) and plasma concentration-time 
profile (B) of PHT after i.p. administration at a dose of 6 mg/kg in rats with (○) 
or without (●) a concomitant i.p. injection of 2 mg/kg CBZ. Data were 






Table 4.12 Neuropharmacokinetic parameters (mean±SD) of PHT after i.p. 
administration of 6 mg/kg PHT with or without the concomitant i.p. 
administration of 2 mg/kg CBZ in rats. 
NeuroPK parameters PHT (n=6) PHT+CBZ (n=6) p-Value 
Cmax (μg/mL) 0.0679±0.0060 0.0633±0.0096 0.26 
Tmax (min) 77±8 73±10 0.685 
AUC0-∞ (μg*min/mL) 13.53±2.95 14.68±2.87 0.524 
AUC0-480(μg*min/mL) 11.94±2.63 12.95±2.94 0.557 
λz (min-1) 0.00629±0.00145 0.00548±0.00049 0.285 
t 1/2, λz (min) 114±20 127±12 0.226 
MRT0-∞ (min) 199.08±32.09 220.00±17.35 0.272 
MRT0-480 (min) 152.82±23.31 167.78±15.88 0.413 








Table 4.13 Pharmacokinetic parameters (mean±SD) of PHT after i.p. 
administration of 6 mg/kg PHT with or without the concomitant i.p. 
administration of 2 mg/kg CBZ in rats. 
PK parameters PHT (n=6) PHT+CBZ (n=6) p-Value 
Cmax (μg/mL) 1.342±0.201 1.459±0.202 0.300 
Tmax (min) 30±11 37±8 0.252 
AUC0-∞ (μg*min/mL) 266.19±52.84 247.05±49.08 0.212 
AUC0-480(μg*min/mL) 218.28±43.17 209.01±38.02 0.510 
λz (min-1) 0.00422±0.00047 0.00450±0.00033 0.215 
t 1/2, λz (min) 166±17 155±11 0.171 
MRT0-∞ (min) 264.77±27.91 241.80±18.52 0.152 
MRT0-480 (min) 164.83±8.99 159.53±5.58 0.089 
CL/F (mL/min) 6.181±1.231 6.641±1.722 0.350 
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CBZ plasma time course (Mean ± SD)
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Figure 4.8 bECF concentration-time profile (A) and plasma concentration-time 
profile (B) of CBZ after i.p. administration at a dose of 2 mg/kg in rats with (○) 
or without (●) a concomitant i.p. injection of 6 mg/kg PHT. Data were 





Table 4.14 Neuropharmacokinetic parameters (mean±SD) of CBZ after i.p. 
administration of 2 mg/kg CBZ with or with out the concomitant i.p. 
administration of 6 mg/kg PHT in rats. 
NeuroPK parameters CBZ (n=6) CBZ+PHT (n=6) p-Value 
Cmax (μg/mL) 0.0193±0.0053 0.0192±0.0048 0.980 
Tmax (min) 70±21 77±15 0.630 
AUC0-∞ (μg*min/mL) 4.97±1.15 4.63±1.13 0.766 
AUC0-480(μg*min/mL) 4.28±1.25 3.91±1.14 0.764 
λz (min-1) 0.00450±0.00056 0.00467±0.00067 0.735 
t 1/2, λz (min) 156±20 151±21 0.747 
MRT0-∞ (min) 256.23±27.34 255.02±22.22 0.951 
MRT0-480 (min) 180.99±12.08 177.74±11.55 0.696 








Table 4.15 Pharmacokinetic parameters (mean±SD) of CBZ after i.p. 
administration of 2 mg/kg CBZ with or with out the concomitant i.p. 
administration of 6 mg/kg PHT in rats. 
PK parameters CBZ (n=6) CBZ+PHT (n=6) p-Value 
Cmax (μg/mL) 0.571±0.177 0.524±0.137 0.768 
Tmax (min) 43±15 62±16 0.241 
AUC0-∞ (μg*min/mL) 151.80±84.86 137.36±55.07 0.842 
AUC0-480(μg*min/mL) 129.28±57.72 117.81±41.23 0.828 
λz (min-1) 0.00532±0.00203 0.00483±0.00083 0.615 
t 1/2, λz (min) 147±55 148±29 0.974 
MRT0-∞ (min) 230.12±74.50 241.09±45.30 0.825 
MRT0-480 (min) 164.04±20.30 172.08±13.34 0.584 
CL/F (mL/min) 4.313±2.285 4.411±1.954 0.962 





The present study was conducted to investigate simultaneously the 
pharmacokinetic interactions of PHT and CBZ in blood and in the central 
nervous system of freely moving rats using the microdialysis as well as vein 
cannulation techniques. Our results indicate that co-administration of PHT and 
CBZ, at the dose of 50 mg/ml for both, increased the neuro-bioavailability of 
each drug but not their plasma bioavailability as indicated by the AUC, Cmax and 
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Tmax values. Microdialysis was again successfully employed in the present study 
using the established animal model. The analytical method developed in this 
study was evaluated to be robust, accurate and reproducible. 
 
As mentioned in Chapter 3, HPPH was not detectable in brain dialysate at a 
low dose of PHT. Likewise, neither could CBZ-E be detected in brain dialysate 
at a low dose of CBZ. It is belived that it would be difficult for HPPH and 
CBZ-E to pass BBB because the two metabolites are more hydrophilic than 
their parent drugs.   
 
Similar to what was proposed on PHT-FBM interaction study, the mechanism 
for the PHT-CBZ interaction was likely due to the modulation on the activity of 
the BBB transporter and/or metabolic enzyme systems. Impacts of drug 
transporter on PHT and CBZ activity have been widely investigated using both 
in vitro and in vivo methods (45; 77; 78; 81). Co-administration of P-gp 
inhibitors, such as cyanide, verapamil or PSC833 (45), significantly enhanced 
the brain uptake of PHT in rats. Increased brain extracellular levels of PHT was 
also found in rats after co-administration of the MRP2 inhibitor probenecid (46). 
CBZ was, in one report, suggested to be a non-P-gp substrate but CYP3A4 
substrate (77). However, another study using microdialysis on rats demonstrated 
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that both PGP and MRP participate in the regulation of extracellular brain 
concentrations of CBZ. Enhanced CBZ in the extracellular fluid of the cerebral 
cortex was achieved by local perfusion with verapamil or probenecid via the 
microdialysis probe (79). It is very hard to draw any conclusion based on 
current observations as well as previous findings (45; 77; 78; 81). However it is 
highly possible that PHT-CBZ neuroPK interaction occurs in response to their 
competitively inhibitory modulation on the transporter activity. 
 
Our results have illustrated the increased PHT and CBZ level in the brain after 
combined use of the AEDs at a dose of 50 mg for PHT and 10 mg for CBZ. 
This is reflected by the significant increase in the bECF AUC levels for both 
drugs. The increased bECF drug bioavailability will perhaps lead to enhanced 
anti-epileptic activity as well as unwanted side effects, such as neuron toxicity. 
It is noteworthy that the increased bECF AUC is accompanied by up-regulated 
bECF Cmax instead of bECF t1/2. Such observations suggest that the increased 
drug bioavailability may be highly dependent of enhanced drug uptake into 
bECF (distribution) from the plasma instead of alterations in their elimination. 
In consideration of the barrier functions of the drug transporter in the BBB, our 
findings further substantiate the possibility that inhibitory modulation of the 




Another finding in this study is that the neuroPK interaction between PHT and 
CBZ is concentration dependent. While at the higher dose of 50 mg/kg (PHT) 
and 10 mg/kg (CBZ), there is a significant increase in drug brain bioavailability, 
such an effect was not observed at the lower dose study. In supportive of 
elucidation on the involvement of drug transporter inhibition, the saturation of 
the transporter might be achieved by PHT and/or CBZ at the dose of 50 mg/kg 
and 10 mg/kg, respectively.  
 
In accordance to what was found in the interaction study of PHT and FBM in 
plasma, at either dose investigated, there was also no significant interactions 
between PHT and CBZ in plasma. In contrast to the significant increase in the 
bECF drug levels upon combined use of the AEDs, the unchanged plasma level, 
perhaps, is a result of more than one modulation processes that at least comprise 
influence on hepatic metabolism and factors involved in renal elimination. The 
modulation effects of PHT and CBZ on hepatic metabolic enzymes, such as 
CYP3A4 and CYP2C19 (84), have been extensively addressed. Nevertheless 
such evidence did not exclude the possibility of more intensive modulation on 
the brain transporter system rather than on other tissue. In previous studies, 
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P-gp substrate drugs, digoxin (64) and morphine (85), all showed more 
intensive brain disposition than other tissues in mdr1a/1b (-/-) mice.  
 
In consideration of the ratio of bECF AUC level to plasma AUC level, however, 
the significant difference between CBZ (50 mg/ml) and CBZ + PHT 
combination groups was abolished (Table 4.10). In this regard, combination use 
of the two drugs might also influence the PK profile of CBZ albeit such an 
effect was not statistically significant. The underlying mechanisms remain to be 
revealed in spite of the complicated effect of CBZ and PHT on drug transporters 
and metabolic enzymes. The present results also reveal that neuroPK 
interactions are not always independent of PK interactions. The moderate 
changes in CBZ PK profile may be partially contribute to the increased CBZ 
bioavailability in bECF in the presence of PHT. 
 
In summary, our studies on neuroPK and PK interactions between PHT and 
CBZ have significant clinical implication that it provides direct evidence of 
enhanced epileptic drug bioavailability at the site of drug action upon 
combination use of the AEDs. To our best knowledge, this is the first report on 
making a comparison between neuroPK and PK profiles of AEDS. It should be 
aware that the enhanced drug bioavailability in bECF will be accompanied by 
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potential up-regulated toxicity to the brain.  
 
On the other hand, AEDs are normally used in chronic basis. The long term 
effect of their combination on their individual bioavailability remains to be 
clarified. Drug transporters, such as P-gp, have been reported to be expressed at 
higher levels in epileptic patients partially due to their long term exposure to 
AEDs (20; 29; 86; 87). In addition, AEDs have shown modulation effect on 
drug transporter expression upon chronic exposure. CBZ was found to induce 
intestinal MDR1 mRNA, MRP2 mRNA, and MRP2 protein but not the P-gp 
protein content in healthy volunteers (81). In this sense, understandings of the 
































The present study investigated the neuropharmacokinetic interactions between 
clinically used AEDs in rats using microdialysis and conventional jugular vein 
cannulation tequniches. HPLC and LC-MS/MS methods were employed for 
analysis of the drug concentrations in plasma and bECF, respectively. Three of 
the AEDs, PHT, FBM and CBM were investigated and drug interactions 
between PHT and FBM as well as PHT and CBM were evaluated.  
 
At the dose of 50 mg/kg for PHT and FBM, concurrent i.p. administration of 
PHT and FBM significantly enhanced the drug bioavailability in the brain as 
demonstrated by higher AUC and Cmax in bECF for both drugs. At the lower 
dose of 6 mg/kg for PHT and 10 mg/kg for FBM, the neuropharmacokinetic 
profiles of the two drugs, however, were not significantly affected when 
compared to their respective profile of drug given alone. In contrast, such a 
trend was not found in the conventional pharmacokinetic studies in plasma that 
co-administration at either dose combination did not significantly affect the 
plasma bioavailability and other PK parameters. With respect to PHT and CBZ, 
co-administration of these two drugs yields similar results as observed in the 
study for PHT and FBM. Co-administration of PHT and CBZ at higher doses of 
50 mg/kg and 10mg/kg respectively, increased the brain drug AUC for both but 
did not significantly alter their plasma bioavailability. At the lower doses of 6 
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mg/kg for PHT and 2 mg/kg for CBZ, neither neuropharmacokinetic nor 
pharmacokinetic interactions was observed. 
 
Our findings provided direct in vivo evidence of neuropharmacokinetic 
interactions between AEDs and therefore have of clinical significance. The 
microdialysis method proved to be a validated effective method for requirement 
of the micro-sampling in the brain. The method provides real time analysis of 
bECF samples and can be applied to neuropharmacokinetic studies and 
disposition studies of other drugs. In addition, the HPLC and LC-MS/MS 
analysis methods for PHT, FBM and CBZ in both plasma and bECF have been 
established. The analytical methods are applicable in future in vitro and in vivo 
studies. 
 
To verify the mechanisms involved in neuropharmacokinetic interactions 
depicted in our study, it is necessary to carry out in vitro studies using cultured 
brain endothelial cells as these cells express drug transporters and form tight 
junctions. These simulate drug transport situations through BBB while avoid 
many complicated systematic processes. The direct interaction of AEDs with 
brain drug transporters remains to be verified as controversial results were 
found in literature reports (28; 46-48; 55; 62; 77; 79; 81). Verification of the 
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expression of the transporters, such as P-gp and MRP, is the prerequisite for 
such mechanism study. The comparable expression levels of the transporters to 
that of the real brain tissues are desirable.  
 
On the other hand, as the function and expression of drug transporter system 
and metabolic enzymes expressed in the BBB is still under evaluation and 
investigation, cultured cell models may not fully represent the complicity of 
BBB. In this sense, studies employing knockout animals (23-25) will provide 
more solid evidence on the neuropharmacokinetic interactions studied in the 
present project. Microdialysis technique remains a beneficial sampling method 
in such knockout animal model. 
 
In addition to the mechanism study, it may be meaningful to conduct the chronic 
study on the basis that AEDs are always administered to patients for a long term 
treatment. Both in vivo and in vitro experiments are necessary in order to reveal 
the potential neuroPK and PK interactions between AEDs and to uncover the 
underlying mechanism. To achieve such a goal, a thorough design on the drug 
dose, time and administration interval are needed to simulate the clinical drug 
regimen. The methodologies involved in this project are still indispensable in 
the investigation on the drug interaction. Other molecular techniques, such as 
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western blot and real time PCR can be utilized to analyze the influence of 
chronic exposure on the expression level of specific drug transporters.  
 
In summary, we provide strong in vivo evidence for neuropharmacokinetc 
interactions between the AEDs of PHT, FBM and CBZ. The findings of this 
project provide clinical significance in AED treatment of epilepsy. However, the 
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